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ABSTRACT OF THE DISSERTATION 
The Genetic Dissection of Isolated Congenital Asplenia in Humans 
By Alexandre Bolze 
Université Paris Descartes  
Thesis director: Jean-Laurent Casanova 
 
Isolated congenital asplenia (ICA) is a rare primary immunodeficiency, first 
described in 1956, that typically manifests in childhood with sudden, life-threatening, 
invasive bacterial disease. Patients with ICA do not display any other overt 
developmental anomalies. The genetic etiology of ICA has remained elusive. I 
hypothesized that ICA results from single-gene inborn errors of spleen development. I 
aimed to decipher the molecular genetic basis of ICA by pursuing a genome-wide 
approach, based on the sequencing of the whole-exome and the detection of copy 
number variations in all patients of our cohort. I found that heterozygous mutations in 
RPSA, ribosomal protein SA, were present in more than half of ICA patients (19/33). I 
then showed that haploinsufficiency of RPSA led to ICA in one kindred at least. RPSA is 
a protein involved in pre-rRNA processing and is an integral part of the ribosome. The 
challenge is, now, to understand the pathogenesis of the disease. How does a mutation 
in a ubiquitous and highly expressed gene lead to a spleen specific phenotype? This 
discovery will set the basis for a broader understanding of the development of the 
spleen in humans and the function of a ribosomal protein. This discovery will also be 
beneficial to the families of patients with ICA, guiding genetic counseling. It will lead to 
prevention of infections in newborns with mutations in RPSA. Finally the method we 
used to analyze the exomes of the ICA cohort will be useful to discover the genetic 
etiology of other genetic diseases.  
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CHAPTER 1 
 
 
INTRODUCTION 
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1.1 The Genetic Theory of Infectious Diseases 
Albert Libchaber, a respected physicist at Rockefeller University, once told me 
that biology and medicine were not real sciences in his opinion. Biologists were telling 
independent stories rather than working on a theory. As an argument, he highlighted the 
fact that life expectancy barely increased in developed countries in the last thirty years 
despite all the resources invested in life sciences. He had a point, although I would 
argue that mathematics would not be a science either if the evolution of the Dow Jones 
was the only criteria considered. In any case, life expectancy has dramatically increased 
at one very specific point in History, at the beginning of the 20th century (Figure 1)1. 
This was primarily due to the wide acceptance of the germ theory of disease, first 
established by Louis Pasteur, and the consequent or parallel improvements in hygiene, 
as well as the development of vaccines and antibiotics. The theory suggested that 
microbes were the cause of many infections and diseases in general. 
However, the germ theory of disease could not account for the fact that some 
people were infected without presenting any symptoms. Charles Nicolle was the first to 
notice this in 1911 in Tunis, while working on typhus. It intrigued him that some guinea 
pigs developed fever while others did not despite being inoculated the same dose of 
typhus. Strikingly when he inoculated the blood from a guinea pig that had contracted 
‘inapparent typhus’ (i.e. with no signs of fever) to another guinea pig, the other guinea 
pig always presented signs of fever, if the dose of inoculum was sufficient2. This 
experiment proved that the first guinea pig had contracted typhus, in spite of the lack of 
fever. Later Nicolle also demonstrated that native children, particularly very young ones, 
contracted a benign form of typhus without developing any apparent symptoms, which 
could only be detected by experimental transmission of typhus by inoculating their blood 
in the monkey or the guinea pig2. This was the first example of inapparent infections. 
Another example is that some children develop a very severe infection after vaccination 
with Bacille Calmette-Guerin (BCG)3, a phenomenon called BCG-itis. Since all the BCG 
vaccines are identical, what could explain that some children develop these severe 
infections whereas the vast majority does not develop any symptoms? 
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Almost 40 years after the discovery of Nicolle, the first explanations for 
inapparent infections started to arise. In 1954, Anthony Allison showed that genetic 
mutations could confer resistance to malaria. Allison was troubled by the very high 
percentage, up to 20% in some African tribes, of carriers of the sickle-cell allele at the 
heterozygous level, despite the fact that being a homozygous carrier led to an early 
death from anemia. He hypothesized that carrying the sickle-cell allele led to a selective 
advantage and showed that indeed, children from an East African tribe carrying the 
sickle-cell allele were less susceptible to infection by Plasmodium Falciparum compared 
to the children from the same tribe not carrying the sickle-cell allele4. However, this 
resistance could only explain ‘inapparent malaria’ for a small percentage of the 
population. This was the beginning of the ‘population genetics’ branch in the field of 
human genetics of infectious diseases. The dominant hypothesis in this branch was that 
common infections (at the population level) with virulent microbes in otherwise normally 
resistant (to infections) patients resulted from the polygenic (complex) inheritance of 
common susceptibility alleles. In parallel, Ogden Bruton described the first primary 
immunodeficiency (PID): X-linked agammaglobulinaemia (XLA, OMIM #300755) in one 
eight-year old boy with multiple infections5. Forty years passed between the clinical 
identification of the specific loss of gamma globulin as the cause for multiple infections 
in one child and the subsequent identification of the gene involved in XLA6; 7. This 
marked the rise of the ‘Mendelian’ branch in the field of human genetics of infectious 
diseases. The investigations tested successfully the hypothesis that rare infections with 
a broad range of weakly virulent microbes and/or multiple, recurrent infections in an 
individual were the result of a rare monogenic PID.  
However none of these two mainstream hypotheses could account for the fact 
that half of the BCG-itis patients were not susceptible to any other infections3. Jean-
Laurent Casanova and Laurent Abel put forward an alternative hypothesis in the 1990s. 
They hypothesized that life-threatening infectious diseases striking otherwise healthy 
children may also result from single-gene inborn errors of immunity1; 8-10. As the aim of 
this thesis is to test this hypothesis, I will highlight the words I thought were important. (i) 
Life-threatening: the focus is on extreme cases. This is one difference with the diseases 
usually looked at by population geneticists. (ii) Otherwise healthy: patients with PIDs 
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were thought to be susceptible to multiple pathogens such as the patients with Severe 
Combined Immunodeficiency (SCID, OMIM #601457) that were susceptible to fungal, 
viral and pyogenic pathogens. The hypothesis of the laboratory is different as it focuses 
on patients with susceptibility to only one type of weakly virulent pathogen, BCG 
vaccine for example. (iii) Children: The hypothesis is formulated in the case of children. 
Children have less time to acquire immunodeficiencies, and thus a defect is more likely 
to be congenital rather than acquired. (iv) Single-gene: one mutation in one gene is 
enough to cause the disease. At the population level however, a specific infection could 
be caused by a collection of highly diverse and possibly immunologically related single-
gene lesions according to this hypothesis. In conclusion, this model, if true, could bridge 
the two previous fields and support a genetic theory of pediatric infectious diseases 
(Figure 2). This new model also led to a considerable expansion of the definition of a 
PID. 
The lab had been testing this hypothesis on different types of infectious diseases 
including mycobacterial disease11, invasive pneumococcal disease (IPD)12, herpes 
simplex encephalitis (HSE)13 and chronic mucocutaneous candidiasis (CMC)14. 
Interestingly a subgroup of patients suffering from recurrent IPD was also diagnosed 
with isolated congenital asplenia (ICA, OMIM #271400). Conversely, ICA patients only 
suffer from encapsulated bacterial infections, mostly IPD. In addition, ICA challenged 
many of the conventional thoughts on PIDs as it is not a hematopoietic defect and the 
prognosis spontaneously improves after early childhood10; 15. The genetic etiology of 
ICA was unknown. The choice was made; I would test the theory of the lab on this 
disease. 
1.2 Isolated Congenital Asplenia 
Asplenia can be functional (i.e. the spleen does not work) as in sickle cell 
disease16. Asplenia can also be acquired after trauma or surgery, or it can be 
congenital. Congenital asplenia is often associated with complex visceral defects, as 
part of the ‘heterotaxy’ syndromes17. The best known among these heterotaxy 
syndromes is the asplenia/polysplenia syndrome (AS; OMIM #208530), which was fully 
documented by Ivemark in 195517. Patients suffering from this syndrome have a 
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complete absence of the spleen (right-sided isomerism), or in some cases two spleens 
(left-sided isomerism) (Figure 3). They also suffer from various anomalies of the heart 
and great vessels, which are usually the most severe aspects of the condition. The 
incidence is about 1/10 000 to 1/40 000 live births15. Mutations leading to AS have been 
identified in various genes controlling left-right laterality18. In contrast the patients with 
ICA lack other developmental anomalies, particularly with respect to their cardiovascular 
systems. 
Since Myerson et al. reported the first case in 195619, only 53 patients with ICA 
have been reported in the medical literature in over 50 years19-42 apart from our own 
recent series of French patients15. ICA is thus an extremely rare PID. However, ICA is 
likely under-diagnosed, for at least three reasons. First, it is a rare disease, and as with 
most rare diseases, awareness is insufficient. Second, this rare disease is not well 
known when compared with other PIDs or other rare diseases, in part, because it has 
received little attention from clinicians and investigators. PIDs were mostly thought to be 
hematopoietic defects and the spleen was/is not the most fashionable organ. Third, ICA 
strikes suddenly and swiftly, with unexpected lethal infections that do not provide 
medical professionals the opportunity to identify ICA. Among the 53 patients reported, 
27 cases were sporadic and 26 were familial, belonging to 11 unrelated families (total of 
38 families worldwide), suggesting there could be a genetic factor. ICA was diagnosed 
in 34 cases in children and in 15 cases in adults; for four cases, the age of the patient 
was not available. There were 24 males and 22 females; the gender was not specified 
in seven cases.  
Sparse reports indicate that most known children with ICA die of fulminant 
bacterial disease – particularly IPD43. There were at least 49 episodes of severe 
bacterial infection in the patients reported with ICA. Twenty-seven patients suffered 
from IPD and five from Haemophilus influenza type b invasive disease. Overall, nine 
patients had several episodes of invasive bacterial disease: two episodes in five 
patients; four of whom died at the second episode, and three episodes in four patients; 
three of whom survived the third infection. Up to 22 of the 53 patients died of 
overwhelming bacterial sepsis. This is thought to result from the combination of two 
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phenomenons. Firstly, asplenic patients have low numbers of IgM memory B cells in 
their blood44. This low number of IgM memory B cells is associated with low levels of 
polysaccharide-specific antibodies. The B cells from the splenic marginal zone are 
important for the secretion of these antibodies44. Secondly, there is a lack of 
phagocytosis of circulating opsonized bacteria in the absence of splenic 
macrophages43. There is no curative treatment for ICA. Therefore patients with ICA are 
protected from infectious complications of asplenia by reinforced and repeated 
conjugated and unconjugated vaccinations against encapsulated bacteria 
(haemophilus, pneumococcus, meningococcus), by daily antibiotic prophylaxis 
(penicillin), and through education of the families and clinicians (in case of sudden 
fever). From these reports, we can only conclude that ICA is a life-threatening birth 
defect and that it remains poorly understood. 
1.3 Aim 
The aim of this thesis is to decipher the molecular genetic basis of ICA. 
1.4 Hypothesis 
I hypothesized that isolated congenital asplenia (ICA) results from single-gene 
inborn errors of spleen development. 
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Figure 1: Mortality curves at various periods of human history, from the Palaeolithic 
period (<10,000 BCE) to modern times (2000 CE).  
Contemporary data for the United Kingdom and Mozambique are available from the 
WHO site (www.who.int/topics/global_burden_of_disease). Life tables for the 
Palaeolithic and Neolithic periods are based on skeleton examinations, assuming that 
60% of newborn infants survived to the age of five, because few very young skeletons 
were found in the burial grounds. The gradual adjustment of the immune system by 
natural selection did not increase life expectancy until the end of the 19th century, due 
to the coevolution of microorganisms and the emergence of new infectious threats. 
Thus, the increase in life expectancy in the 20th century does not reflect the sudden and 
global natural selection of high-quality immune genes. The area between the four 
ancient curves and the curve for the UK in 2000 corresponds to ׽65% of individuals 
currently alive. Most of these individuals have retained specific immunodeficiencies 
masked by medical progress. 
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Figure 1: Mortality curves at various periods of human history, from the Palaeolithic 
period (<10,000 BCE) to modern times (2000 CE). 
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Figure 2: Life-threatening infectious diseases of childhood: single-gene inborn errors of 
immunity? 
Schematic representation of a hypothetical, age-dependent, human genetic architecture 
of infectious diseases. The hypothesis of the laboratory suggests that single-gene 
human variants make an important contribution to the determinism of life-threatening 
infectious diseases of childhood, in the course of primary infection. By contrast, 
predisposition to severe infectious diseases in adults, in the course of microbial 
reactivation from latency or secondary infection, is less influenced by germline human 
genetic variations, resulting in a more complex  and, perhaps, polygenic contribution. 
Somatic and epigenetic processes are likely to play a greater role with advanced age. 
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Figure 2: Life-threatening infectious diseases of childhood: single-gene inborn errors of 
immunity? 
 
 
  
10

Figure 3: The anatomic spectrum of organ laterality. 
Figure adapted from45 (A) Situs solitus. Normal position of the organs in the human 
body. (B) Right atrial isomerism. The liver is midline, there are 2 eparterial bronchi, the 
position of the stomach and cardiac apex is indeterminate, and there is asplenia. (C) 
Left atrial isomerism. The liver is midline, there are 2 hyparterial bronchi, the position of 
the stomach and cardiac apex is indeterminate, and there are multiple spleens. (D) 
Situs inversus. (E) Isolated congenital asplenia (ICA). 
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Figure 3: The anatomic spectrum of organ laterality. 
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COHORT OF PATIENTS WITH ICA 
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In order to test my hypothesis, I needed biological material, gDNA at least, from 
ICA patients. The more patients we would recruit, the more powerful the genetic study 
could be and the more likely I was going to be able to decipher the molecular genetic 
basis of ICA. This was the most important part of the project.  
2.1 French retrospective survey 
I was lucky because as I started in the lab, they conducted a French national 
retrospective survey, by mailing questionnaires to chiefs of pediatric services at public 
hospitals affiliated with immunological, infectious, or intensive care societies to learn 
more about ICA. The survey covered the years 1979-200815. To be included in the 
survey, a patient had to be diagnosed with ICA based on the presence of Howell-Jolly 
bodies on peripheral blood smears (sign that the spleen is not functional), the lack of 
detectable spleen by abdominal ultrasound (US), and no detectable cardiovascular 
malformation by echocardiography. The data were collected from 294 of 443 pediatric 
units solicited. Twenty patients from 10 kindreds, neither related to each other nor 
consanguineous, were included15. Four cases were sporadic, 16 were familial, and the 
sex ratio was balanced (12:8). Out of the six multiplex families, four suggested 
autosomal dominant inheritance. Median age was 12 months at first infection (range: 2-
516), 11 months at diagnosis of asplenia (range: 0-510), and 9.9 years at last follow up 
(range: 0.7-52). Fifteen patients suffered from 18 episodes of invasive bacterial 
infection, mainly caused by Streptococcus pneumonia (61%). The outcome was poor, 
as nine patients (45%) died of fulminant infection. This data clearly suggested that ICA 
is more common than initially estimated, with an incidence of about one per million live 
births (0.51 per million). This would mean that there is a minimum of 3,500 cases of ICA 
in the world.    
2.2 International recruitment 
This survey was a retrospective survey. Therefore we were able to gather clinical 
data, the key to understand the epidemiology of the disease, but not biological samples 
from the patients, which are the keys to undertake our genetic analysis. We, thus, tried 
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to recruit more patients from world-wide collaborations. The strategies used were the 
following:  
(i) Contacting corresponding authors of papers reporting a patient with ICA. We 
were able to recruit only one family this way (kindred G in Figure 4) because 
there were only few recent papers, and the majority never responded to my 
emails.  
(ii) Contacting physicians that already collaborate with us, in particular physicians 
that collaborate with us on the IPD project, or that already recruited ICA 
patients. 
(iii) Publishing papers on ICA to alert physicians that one team is working on it. 
This was one of the goals of our paper in The Journal of Pediatrics reporting 
the results of the French national retrospective survey15. However few if none 
have contacted us after this publication. More success was encountered after 
the paper reporting the role of the Pbx/Nkx2-5/p15 pathway in the 
development of the spleen46. Two unrelated patients, one from the US and 
one from Australia, contacted us directly to participate in the study. They read 
the paper because it was advertised on many news websites thanks to Weill 
Cornell Medical College media office.  
(iv) Presenting the project at conferences such as ESID (European Society of 
primary Immuno Deficiencies). Jean-Laurent is relentlessly traveling all 
around the World to recruit patients to test the hypothesis. However ICA 
being a ‘newer’ project in the laboratory, he did not talk frequently about 
asplenia.  
In 3 years, we were able to recruit 24 kindreds with at least one ICA patient (Figure 4, 
Table 1). In total, there were 37 ICA patients and 7 possible ICA patients in these 24 
kindreds. People were declared possible ICA patients when the diagnosis was unclear, 
or when the patients deceases due to severe bacterial infections and had a family 
history of ICA but their spleen was not analyzed. We were able to obtain gDNA from 35 
of these patients (34 + 1 possible). The ratio male/female was 21/16. ICA segregates as 
an autosomal dominant (AD) trait in five kindreds (A-E), whereas it looks to segregate 
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as an autosomal recessive (AR) trait in one kindred: F. For the two other multiplex 
families, and the 16 sporadic cases, it is hard to conclude anything before the 
identification of the genetic etiology of ICA. Finally the clinical information remains 
unequal depending on where the patient was recruited. Therefore it would be inexact to 
conclude on the number of patients presenting severe infections etc… 
2.3 Ideas 
The recruitment of patients was the longest part of this thesis. For example, we 
were able to contact a physician in Toulouse following a family with 2 ICA patients. The 
patients agreed to participate but after a year of emails, phone calls and paperwork we 
are still not able to enroll them in the study because the Toulouse hospital has not yet 
been approved as a collaborative center for us. Other patients were recruited but it took 
more than a year to have the physicians send detailed case reports. Moreover I had to 
exclude some samples after discovering they were not ICA cases.  
This seems inherent to any new project and there is nothing abnormal. I was 
actually very lucky to be able to recruit so many families. At the time of Twitter, 
Facebook and the Do It Yourself generation, there must be a faster approach. This 
approach would link directly the patient with the researcher. Patients interested in 
research would be able to contact the laboratory of their choice working on their 
disease. They would be able to fully participate in the study. If a patient wants to 
participate and discuss the literature on the topic with the researchers, why would he 
not have the right to? Why does the patient, frequently a tax payer, is not able to have 
access to the result of the research performed on him? In our lab some patients 
declined participating to studies, after being initially very interested, when told we would 
not be able to communicate any results with them. Without a change in the IRB policies 
and the way human genetics is being pursued in academia, my guess is that all future 
discoveries in the field will be made by biotech companies.  For example, 23andMe has 
started research projects using the pool of customers wanting to have their genotyping 
done. They named it: 23andWe: https://www.23andme.com/research/ . They were able 
to recruit more than 5,000 patients with Parkinson disease and already published 
results in open access journals47; 48. 23andMe will soon have the genotype and DNA of 
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more than a million people, with a majority willing to participate in research and learn 
more about them. This is a great opportunity for them and for us as well. Patients will 
have their genome in hand. Giving them the opportunity to share it with the laboratory of 
their choice would be a great step forward.  
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Figure 4: Pedigrees of the ICA cohort. 
Black symbols represent ICA patients. Gray symbols represent individuals not 
diagnosed with ICA, but likely to be ICA patients, due to their infectious disease history 
and familial history. Capital letters above pedigrees refer to a specific kindred (these 
letters will be used to refer to one family if needed later in the thesis). Numbers 
preceded with “JL” indicate patients sequenced by exome and their exome number. 
These will be used in some of the exome results’ tables.  
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Figure 4: Pedigrees of the ICA cohort. 
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Table 1: Geography of the ICA cohort. 
Kindred Country1 Originofthemother Originofthefather Modeofinheritance
hypothesized
A UnitedKingdom Caucasian Caucasian AD
B France SubsaharanAfrica
(Congo)
SubsaharanAfrica
(Congo)
AD
C Reunionisland Caucasian Tamoul AD
D Italy Caucasian Caucasian AD
E US Caucasian Caucasian AD
F France Caucasian Caucasian AR
G UnitedKingdom Caucasian Caucasian AR
H France Caucasian Caucasian AR
I France Caucasian noinformation ?
J Spain Caucasian Caucasian ?
K France WesternAfrica
(Cameroun)
Caucasian ?
L Colombia Colombian unknown ?
M France Caucasian Caucasian ?
N Israel Israel(jewish) Israel(jewish) ?
O France Caucasian Caucasian ?
P Israel Israel(jewish) Israel(jewish) ?
Q UnitedKingdom Caucasian Caucasian AR
R France Caucasian Caucasian ?
S Sweden Caucasian Caucasian ?
T Sweden Caucasian Caucasian ?
U Sweden Caucasian Caucasian ?
V Sweden Caucasian Caucasian ?
W France Caucasian Caucasian AR2
X France Caucasian Caucasian ?

1: country where they live and where they were diagnosed.  
2: all grandparents from the same village.  
AD: autosomal dominant 
AR: autosomal recessive 
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 To test my hypothesis I had to look for mutations that might be disease-causing 
in the 35 ICA patients of our cohort for whom I had gDNA. At the beginning of my PhD, 
the only way to do it was by Sanger sequencing (see Material and Methods). This 
method required to sequence each exon of each gene one by one. I had to select good 
candidate genes as it was impossible to sequence the 20,000 genes of the genome.  
3.1 Genes involved in the development of the spleen 
The genetic etiology of ICA was unknown in humans. The generation of 
genetically engineered mouse models has led to the discovery of a limited number of 
genes, mostly encoding transcription factors, which are required for the accurate 
temporal and spatial coordination of cell-fate specification, cell proliferation, and 
differentiation during embryonic spleen development. These cellular processes are 
disrupted in embryos deficient for Nkx2-3, Nkx3-2, Pbx1, Sox11, Wt1, and Tcf2149-54, all 
of which are normally expressed within the spleen primordium, and also disrupted in 
embryos deficient for Barx1 and ElavI155; 56. The human orthologs of these genes 
whose mutations cause asplenia in mice are candidate genes in patients with ICA 
(Table 2). However these mutant mice all exhibit spleen agenesis or hypoplasia, 
accompanied by other organogenesis defects. There is a stronger candidate gene for 
human ICA, as deficiency in Tlx1 (also known as Hox11) causes ICA in the mouse 
model57.There is therefore at least one gene that seems to be specific for spleen 
genesis, at least in the mouse model (Table 2).  
3.2 Genes mutated in patients with syndromic asplenia 
A number of patients not included in our cohort present syndromic asplenia, i.e. 
asplenia in the context of other developmental defects. For example, about a third of 
patients with heterotaxy syndrome have no spleen58. The genetic etiologies of some of 
these traits have been partially identified18. We hypothesized that ICA might be allelic 
with these syndromes, i.e. that some ICA patients might carry mutations in these 
syndromic asplenia-causing genes listed in Table 2. Human SLC29A3 deficiency is one 
example to back up this hypothesis. Homozygous loss of function mutations in 
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SLC29A3 have been shown to lead to a wide spectrum of syndromes such as the H-
syndrome, type I diabetes, or familial Faisalabad histiocytosis59. Even more striking was 
the fact that siblings with the same disease-causing mutation could have different 
clinical phenotypes. For example one brother could present histiocytosis, 
hyperpigmentation and type I diabetes whereas the sister only presented one of the 
clinical phenotypes: histiocytosis59.  It was therefore possible to hypothesize that some 
ICA patients were mutated in genes involved in heterotaxy syndrome or other 
syndromes with asplenia and presented a partial clinical phenotype. 
These syndromes include the heterotaxy syndrome with or without primary ciliary 
dyskinesia (PCD). Since the first case report of a patient with ciliary abnormalities and 
asplenia in 200360, a study showed that 6.3% of the PCD patients had heterotaxy, some 
of these possibly having no spleen61. In humans, mutations in 10 genes had been 
shown to cause heterotaxy syndrome with PCD62-70  (Table 2). Heterotaxy can also be 
caused by mutations in genes that are not involved in PCD71-80 (Table 2). Most of these 
genetic defects are autosomal and seem to be dominant, making the corresponding 
genes good candidates for autosomal dominant or sporadic ICA. Others are X-linked 
recessive traits, and hence good candidates for sporadic ICA in young males. Other 
syndromes where asplenia was observed were: autoimmune polyglandular syndrome 
type I due to mutations in AIRE81, hyper-IgE syndrome due to DOCK8 deficiency82, 
ATR-X syndrome due to mutations in ATR-X83 and finally HO-1 deficiency84.  Human 
heme oxygenase-1 (HO-1) deficiency is particularly striking as the 3 cases reported 
have the same phenotype including asplenia, hemolysis and nephritis84-86.  
3.3 Failure of the approach 
In total I identified 34 genes that could lead to ICA according to the knowledge 
available in 2009 (Table 2). However, only TLX1 appeared, to me, to be a very good 
candidate. Some of the other genes felt unlikely. At least, it seemed unlikely that all ICA 
cases would only be phenocopies or incomplete phenotypes of a syndromic asplenia 
unless physicians misdiagnosed some of the patients.  
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I sequenced TLX1, PBX1, SOX11, TCF21, NKX3-2, BAPX1, BARX1, OFD1, and 
CRELD1 in this order. The sequencing did not lead to any interesting mutation, or more 
specifically to any coding non-synonymous, and not common variation. The logic would 
have been to continue sequencing one by one the remaining genes. However the 
technique of whole-exome sequencing started to be available at the end of 2009. I was 
very lucky because the genomic facility of Rockefeller was a pioneer in the use of this 
technique and Jean-Laurent decided we would start using this technique instead of 
Sanger sequencing. We would keep the list of candidate genes, as genes to look for 
with special attention when analyzing the exome sequences. 
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Table 2: List of candidate genes to be sequenced in ICA patients. 

Isolated
Congenital
Aspleniainthe
mousemodel
Aspleniaand
developmental
syndromesother
thanheterotaxyin
themousemodel
Heterotaxywith
Primaryciliary
dyskinesia(PCD)
Heterotaxy
withoutPCD
Othersyndromes
withasplenia
Tlx1 Nkx2Ͳ3 DNAI1 ZIC3 AIRE
 Nkx3Ͳ2 DNAH5 ACVR2B DOCK8
 Pbx1 DNAH11 LEFTYA ATRX
 Sox11 DNAI2 CFC1 HOͲ1
 Tcf21 TXNDC3 CRELD1 
 Wt1 RPGR NODAL 
 Barx1 KTU GDF1 
 ElavI1 RSPH9 TDGF1 
  RSPH4A INV 
  OFD1 NKX2Ͳ5 
   BCOR 

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In our grant application for the March of Dimes in the fall of 2009 we mentioned 
we would use whole-exome sequencing (WES) to reach our aim. They rejected our 
application and our genome-wide strategy arguing we had no proof this approach could 
work. It was true at that time as the first paper identifying the genetic etiology of a 
mendelian disorder using exome sequencing was in 201087. We thus decided to try 
WES on an easier case as a proof-of-principle that the technique could work in our 
hands. Mike Horn trained by crossing Greenland before embarking on a non-motorized 
tour of the Arctic Circle. He took nine days to cross Greenland on skis with the help of a 
kite.  
4.1 Clinical features of patients from a large consanguineous family 
An ‘easy’ case for us meant to test WES on a family where the hypothesis that 
the disease would be a mendelian trait was the strongest and the number of genes to 
look at the smallest. Therefore we investigated the molecular basis of a condition 
affecting at least four members of an extended consanguineous kindred of Pakistani 
origin (Figure 5A) with a complex infectious phenotype, with both viral and bacterial 
infections, congenital cardiovascular malformations, biological features of auto-immune 
lymphoproliferative syndrome (ALPS, MIM 601859) (high circulating CD4-CD8-TCRĮȕ+ 
T-cell (DNT) counts, and elevated IL-10 and FasL serum levels) but no clinical features 
of ALPS (Table 3).  
The affected children suffered from recurrent, stereotypical episodes of fever, 
encephalopathy and mild liver dysfunction (modestly elevated transaminases without 
cholestasis, metabolic derangement or synthetic defects), sometimes accompanied by 
generalized seizures that were difficult to control. Episodes lasted several days, 
sometimes requiring intensive care, and cranial imaging in three patients (P1, P3 and 
P4 [IV.2, IV.4 and IV.5 in Figure 5]) suggested atrophy, despite subsequent recovery in 
two of these patients (P1 and P3). For some of the episodes, it was possible to identify 
a viral trigger: varicella zoster virus (VZV), measles mumps rubella (MMR) attenuated 
vaccine, parainfluenza virus and Epstein-Barr virus (EBV). The index case, P3, died at 
the age of four years, during such an episode. In addition, fatal invasive pneumococcal 
disease occurred in two children (P1 and P2), and abnormally high counts of Howell-
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Jolly bodies were detected in the two remaining patients (P3 and P4), despite the 
presence of a spleen. The identification of Howell-Jolly bodies on peripheral blood 
smears is the most reliable indicator of impaired splenic phagocyte function (including 
functional or anatomical asplenia)15. Neither P3 nor P4 suffered from IPD, probably 
because they were on antibacterial prophylaxis treatment from early infancy. These 
observations suggest that functional hyposplenism underlied IPD in patients P1 and P2. 
This clinical syndrome had never before been described (no MIM number). In the 
previous generation, another five family members had died in childhood, two with 
“epilepsy” and two from infection (pneumonia and measles, respectively) (data not 
shown), suggesting that there may have been up to nine patients with this disorder in 
these two generations of this kindred. 
4.2 Whole-exome sequencing and Linkage analysis 
We hypothesized that this syndrome would segregate as an autosomal recessive 
trait. We investigated its genetic etiology, by combining genome-wide linkage analysis 
by homozygosity mapping with whole-exome sequencing87. For the linkage analysis, we 
genotyped three affected patients (P2, P3, P4) their parents (III.1, III.2, III.3, III.4) and 
one healthy sibling (IV.1) with the Affymetrix 500K SNP array or the Affymetrix 6.0 
array. No material was available for P1. Homozygous regions were detected with the 
HomozygosityMapper genome browser. Two regions (>1 Mb) were homozygous in the 
three affected patients and heterozygous in other members of the family: an 8 Mb 
region on chromosome 11 (between rs4930243 and rs7926553, bp position: 
g.68,499,874 – g.76,470,079, hg18, NCBI 36.1) and a 9 Mb region on chromosome 18 
(between rs9959449 and rs12327522, bp position: g.60,703,632 – g.70,387,399, hg18, 
NCBI 36.1). The regions were further confirmed by typing microsatellite markers 
(Figure 6).  
In parallel to the linkage analysis, we sequenced the exome of P3 with the 
SureSelect human All Exon kit (Agilent Technologies). The sequences obtained were 
aligned to the reference genome (hg18 build), with the BWA aligner. Three open-source 
packages were used for downstream processing and variant calling: the Genome 
analysis toolkit (GATK)88, SAMtools89 and Picard Tools. Substitution calls were made 
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with GATK UnifiedGenotyper. All calls with a read coverage 4x and a phred-scaled 
SNP quality of 30 were filtered out. All the variants were annotated with SeattleSeq 
SNP annotation. In total, we identified 23,146 variations. 67 variants were found in the 
chromosome 11 candidate region, and 14 variants were found in the chromosome 18 
candidate region (Table 4). Comparisons with the NCBI dbSNP build 129, the 1000 
Genomes project database and our in-house database (composed of 70 exomes at that 
time), identified only one nonsynonymous variant that had not been reported before and 
mapped to the chromosome 11 region. No previously unreported nonsynonymous 
variant mapping to the linked region on chromosome 18 was identified. The variant 
identified was a missense homozygous c.315T>G in exon 2 of FADD (NM_003824.3, 
MIM 602457) that changes Cysteine at amino acid position 105 to Tryptophan, 
p.C105W (C105W) (Figure 5B and Figure 7). Cysteine at amino acid position 105 is 
highly conserved throughout evolution (Figure 5C). We validated this variant by Sanger 
sequencing on genomic DNA from peripheral blood and on cDNA from EBV-
transformed B cells (EBV-B). This variant segregated with the disease status in all 
family members examined (Figure 5A) and was not found in 282 Pakistani controls, 
suggesting that it is not an irrelevant polymorphism.  
4.3 In vitro functional characterization the C105W FADD mutation 
FADD was first described as an adaptor protein interacting with the apoptosis-
inducing  surface receptor Fas90. It has since been shown to interact with various 
partners and to participate in many other cellular processes, such as autophagy, 
inflammation, innate immunity, cell proliferation, and tumor development91; 92. Thus, we 
hypothesized that the FADD mutation was responsible for the complex clinical 
phenotype of the affected individuals. To test this hypothesis, we assessed the 
expression of FADD mRNA levels in EBV-B cells by quantitative RT PCR. We found 
that FADD mRNA levels in the EBV-B cells from P3 (C105W/C105W) were similar to 
those in the EBV-B cells from IV.1 (WT/WT) (data not shown). However, FADD protein 
levels were clearly lower in primary fibroblasts from P4 (~16%) than in primary 
fibroblasts from a healthy control (Figure 5D, E). Similarly, FADD protein levels were 
lower in the EBV-B cells from P3 (~21%) and III.1 (WT/C105W) (~62%) than in the 
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EBV-B cells from IV.1 (Figure 5D, F). Residue C105 is located in alpha-helix 1 of the 
FADD death domain (DD), at the interface of the Fas/FADD complex93. We tested the 
effect of the C105W mutation on FADD folding stability and Fas-FADD interaction with 
recombinant Fas DD and FADD DD proteins. The C105W mutant protein was folded, as 
shown by differential scanning calorimetry (DSC), but the folding stability of the mutant 
protein was lower than that of WT FADD, by ~10°C (Figure 5G). We then assessed the 
effect of the mutation on Fas-FADD complex stability using a gel co-purification assay in 
the presence of increasing concentrations of NaCl (Figure 5H). Binding levels for 
C105W FADD and Fas were clearly lower than those for WT FADD, suggesting that the 
primary Fas-FADD complex was less stable. Thus, the C105W mutation in FADD 
strongly decreases steady-state protein levels and impairs the interaction of the residual 
FADD protein with Fas.  
FADD forms a critical bridge between the death receptor Fas and caspase-8 
(MIM 601763), in a multimolecular array known as the death-inducing signaling complex 
(DISC)94. We therefore studied Fas-induced apoptosis in the patients’ cells. 
Phytohemagglutinin-stimulated peripheral blood lymphocytes (PHA blasts) from P4 
displayed impaired apoptosis (viability >50% higher than for controls) when challenged 
with cross-linked Fas ligand (FasL), similar to Fas-deficient cells (Figure 8A). In 
addition, EBV-B cells from P3 displayed impaired apoptosis when Fas was cross-linked 
with agonistic Fas-specific antibody (Apo1.3) (Figure 8B). In keeping with this finding, 
investigations of the surviving patient P4 revealed several features classically 
associated with ALPS due to Fas95 or FasL96 deficiency, and more rarely associated 
with deficiencies of caspase-8 or caspase-10 (MIM 601762)97; 98. P4 displayed an 
expansion of the population of mature CD4-CD8-TCRĮȕ+ T cells (DNT) in peripheral 
blood as well as elevated serum levels of IL10 and soluble FasL (Table 3 and Figure 
8C, D). Our data confirm that the FADD C105W variant impairs apoptotic function both 
in vitro and in vivo, resulting in biological features of ALPS despite the lack of clinically 
evident autoimmunity or lymphoproliferation. T-cell proliferation in response to various 
stimuli was normal (Figure 8E), contrasting with findings for caspase-8 deficient 
individuals97 and mice with FADD deficiency specific to T or B cells99.  
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The laboratory findings for the FADD-deficient patients were typical of ALPS, but 
clinical presentation was dominated by features absent from classical ALPS, leading to 
early death. In addition to IPD, FADD-deficient patients suffered from recurrent 
episodes of encephalopathy and liver dysfunction with fever. These were sometimes 
triggered by viral infection (Table 3). Previous studies in mouse embryonic fibroblasts 
(MEFs) suggested that FADD plays a crucial role in type I interferon (IFN) -dependent 
antiviral immunity91; 100. We therefore tested the hypothesis that the unusually severe 
illnesses associated with viral infections in FADD-deficient patients might be due to an 
impaired type I IFN-dependent antiviral response, by assessing the antiviral effect of 
IFN-Į in vesicular stomatitis virus (VSV)-infected P3 and IV.1 EBV-B cells. STAT1-
deficient EBV-B cells, lacking a key type I IFN responsive pathway100; 101, were included 
as controls. Prior treatment with IFN-Į protected both P3 and IV.1 cells from VSV-
induced cell death until 36 h post infection (Figure 9A). However, IFN-Į-treated P3 cells 
eventually succumbed to VSV infection, whereas IFN-Į-treated IV.1 cells remained 
protected until 60 h post infection (Figure 9A, B). These results suggest that the IFN-Į-
responsive pathway is intact, but that the positive feedback of IFN signaling is impaired 
in FADD-deficient cells. Interferon regulatory factor 7 (IRF7), induced by autocrine type I 
IFNs, is known to play a critical role in the positive feedback of IFN signaling, by 
inducing IFN-Į gene family members. We found that the induction of IRF7 in response 
to VSV infection was impaired in P3 cells, despite levels of IFN-ȕ induction similar to 
those in IV.1 cells (Figure 9C). These data provide a molecular basis for the increase in 
susceptibility to viral diseases in FADD-deficient patients.  
4.4 Human FADD deficiency and functional asplenia 
By contrast, we can only speculate about the mechanisms underlying the 
developmental abnormalities within this kindred. P3 displayed pulmonary atresia (MIM 
178370) and P4 had a left-sided superior vena cava (SVC) draining into the left atrium, 
both of which are rare as sporadic defects and were probably caused by FADD 
insufficiency. Indeed, mice with a null mutation in FADD are not viable, owing to 
embryonic defects, including cardiac abnormalities, such as thinning of the ventricular 
myocardium. Moreover, FADD expression in mice, at E11.5, is detected not only in the 
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myocardium102, but also in the brain, liver and developing vertebrae102. Spinal anatomy 
appeared normal in all FADD-deficient patients, but hepatic and cerebral dysfunctions 
were clearly key elements of the disease phenotype. The mild portal fibrosis observed 
on liver biopsy in two patients (Figure 10 J-L), should be considered as sequelae of 
FADD deficiency. Finally, FADD seems to be important for the development of a 
functional spleen in humans, as demonstrated by the presence of Howell-Jolly bodies – 
the hallmark of a lack of splenic function – in the blood smears of P3 and P4.  In P2, a 
limited post mortem examination of lymph nodes, spleen and thymus revealed no 
histological features of ALPS or other lymphoid tissue abnormalities (Figure 10). 
However the spleen showed an expanded, congested red pulp containing increased 
neutrophils, consistent with sepsis. Moreover, the normal cord-sinus architecture of the 
red pulp was not readily apparent; reticulin deposition appeared disordered, normal 
sinusoidal “barrel-hoop” fibres were not identified and macrophages appeared 
haphazardly arranged (Figure 10 C-I). Examination of spleen histology in other affected 
individuals is unlikely to be possible, thus precluding firm conclusions upon relationship 
between human FADD deficiency and disordered red pulp microarchitecture. The 
prominence, but incomplete penetrance of cardiac, hepatic and splenic abnormalities in 
the clinical phenotype strongly suggests the existence of organ-specific effects of FADD 
deficiency worthy of further study in suitably designed mouse models.  
4.5 The identification of human FADD deficiency is a proof of principle that WES 
can be applied to discover the genetic etiology of ICA  
In conclusion, we described the clinical features of an autosomal recessive 
inherited disorder with biological features of ALPS, susceptibility to bacterial and viral 
infections, and developmental abnormalities. Furthermore, we have determined its 
genetic etiology, resulting in FADD deficiency in the affected children, by genome-wide 
linkage analysis and whole-exome sequencing. Finally, we have dissected the 
molecular mechanisms of disease for several aspects of this phenotype, including 
bacterial susceptibility (functional hyposplenism), viral susceptibility (impaired IFN 
immunity) and features of ALPS (impaired Fas-dependent apoptosis). Other 
phenotypes, particularly those of a developmental nature, remain unexplained but are 
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probably due to the disruption of Fas-independent pathways, as they were not 
documented in Fas-deficient patients. These unanticipated findings highlight the power 
of exome sequencing used in combination with genome-wide linkage analysis within 
consanguineous families. In parallel Minji Byun, my benchmate, had also used 
successfully WES without linkage analysis to discover that STIM1 deficiency leads to 
predisposition to Kaposi Sarcoma in humans103. With these two proofs-of-principles we 
were ready to use this approach on the ICA cohort.  
  
34

Figure 5: Characterization of an inherited FADD mutation. 
(A) Pedigree of the Pakistani family. Black symbols indicate patients. Gray symbols 
indicate siblings in the parents’ generation who died early in childhood with clinical 
symptoms related to the disorder observed in P1 to P4. Haplotypes of FADD are 
indicated, as M stands for c.315T>G and WT for the wild type allele. (B) Schematic 
diagram of FADD protein showing the death effector domain (DED) and the death 
domain (DD). The location corresponding to the mutation is indicated by an arrow and 
the predicted amino-acid substitution is shown. (C) Evolutionary conservation of the 
FADD region containing amino acid residue C105 (indicated by the arrow). (D) FADD 
immunoblot in primary fibroblasts and EBV-B cells from patients and controls. 
Experiments were carried out with two different antibodies: a mouse monoclonal 
antibody against the C-terminus of FADD (#610399, BD Biosciences) and a rabbit 
polyclonal antibody against the residues surrounding Ser194 in human FADD (#2782, 
Cell Signaling). Similar results were obtained with both antibodies. GAPDH was used as 
a loading control. A representative blot with the monoclonal antibody is shown (n=6). (E-
F) FADD protein levels in primary fibroblasts (E) and EBV-B cells (F) determined on the 
basis of the intensity of the signal on immunoblots and normalized with respect to 
GAPDH levels. A mean of six experiments is shown. Error bars indicate the SEM. (G-H) 
Effect of the C105W mutation on the stability of FADD DD folding and the Fas – FADD 
complex. (G) Differential scanning calorimetry (DSC) analysis of WT and C105W His6-
FADD DD proteins. (H) Fas/FADD complex stability assay. The retention of FADD DD 
(WT or C105W) with immobilized His6-Fas DD was assessed with various 
concentrations of NaCl, as previously described19 (E is imidazole elution of remaining 
complex after the final NaCl concentration). 
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Figure 5: Characterization of an inherited FADD mutation. 
36

Figure 6: Haplotypes of microsatellites sequenced inside the two linked regions on 
chromosome 11 and chromosome 18.  
18 microsatellites were sequenced in the chromosome 11 region and 2 in the 
chromosome 18 region. In bold, microsatellites with a homozygous haplotype. And 
inside frames are homozygous stretches found by linkage analysis. The black line is 
here to locate the position of FADD 
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Figure 6: Haplotypes of microsatellites sequenced inside the two linked regions on 
chromosome 11 and chromosome 18. 
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Figure 7: Illumina sequencing reads displayed for patient P3. 
Reads overlapping the mutation in exon 2 of FADD (bp position g.69,729,880 – 
g.69,729,949, hg18, NCBI 36.1) show the homozygous T>G base pair substitution. 
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Figure 7: Illumina sequencing reads displayed for patient P3. 
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Figure 8: Characterization of the ALPS phenotype. 
(A) Activated PBLs from normal volunteers (Ctrls), patient P4 and a heterozygous Fas 
deficient patient were stimulated with recombinant FasL (r-FasL) and cell viability was 
analyzed. The proportion of live cells in the presence of r-FasL is displayed as a 
percentage of live cells in the presence of enhancer alone, for each sample. (B) EBV-B 
cells from P3, IV.1 and a Fas-deficient patient were treated with an antibody against Fas 
(Apo-1.3), in the presence of rabbit anti-mouse Ig (Ramig), for 6 h and analyzed for 
early apoptosis. The percentage of cells that were apoptotic was calculated as the 
percentage of cells positive for AnnexinV and negative for propidium iodide staining.  
NS indicates that the cells were incubated with Ramig only. A mean of three 
independent experiments is shown. Error bars indicate the SEM. (C) FasL levels in the 
serum of P4 and eight healthy controls (Ctrls). (D) IL-10 levels in the serum of P4 and 
eight healthy controls. IL-10 values were normalized with respect to the mean of the 
control samples. (E) Proliferation assay. Proliferative responses to various stimuli (PHA, 
5 ȝg/ml; IL-2, 500 U/ml; concanavalin A, 5 ȝg/ml; anti-CD3 (OKT3), 0.1 ȝg/ml; PMA, 50 
ng/ml; ionomycin, 0.1 ȝg/ml). P3 and P4 responded similarly compared with the two 
contols: C1 and C2. 
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Figure 8: Characterization of the ALPS phenotype. 
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Figure 9: Impaired antiviral immunity.  
(A) EBV-B cells from P3, IV.1, and a STAT1-deficient patient were infected with VSV at 
a multiplicity of infection (MOI) of 1, with or without prior treatment with 100 IU/ml of 
IFN-Į for 24 h. Cell mortality was assessed by measuring the amount of LDH released 
into the medium. For STAT1-deficient cells, results are shown only until 36 h post 
infection, due to high levels of spontaneous LDH release at later time points. A mean of 
three independent experiments is shown. Error bars indicate the SEM. (B) EBV-B cells 
from P3, IV.1 and a STAT1-deficient patient were either left untreated (NT, bars in 
white) or treated with 100 IU/ml IFN-Į for 24 h (IFN-Į, bars in black), prior to infection 
with VSV at a MOI of 0.1, and were harvested 48 h post infection. VSV titers were 
determined on Vero cells. A mean of three independent experiments is shown. Error 
bars indicate the SEM. (C) EBV-B cells from P3 or IV.1 were infected with VSV at a MOI 
of 10. Cells were harvested at the indicated time points, and total RNA was extracted. 
IFN-ȕ and IRF7 mRNA levels were determined by quantitative RT-PCR. Threshold 
cycles normalized with respect to those of GUS (ǻCT) are plotted as 2-ǻCT. A mean of 
three independent experiments is shown. Error bars indicate the SEM.  
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Figure 9: Impaired antiviral immunity. 
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Figure 10: Histopathology of P2 (A-K, post-mortem, 14 months) and P4 (L, 22 months). 
(A) Normal thymic architecture; increased cortical tingible body macrophages consistent 
with a stress response (P2, H&E stain, original magnification x100). (B) Normal-
appearing reactive lymph node with follicular hyperplasia (P2, H&E stain, original 
magnification x40). (C) Low power view of the spleen showing expanded, congested red 
pulp with relatively reduced white pulp (P2, H&E stain, original magnification x20). (D) 
White pulp nodule containing a follicle with a reactive germinal centre, but no marginal 
zone hyperplasia, arising from a peri-arteriolar lymphoid sheath (P2, H&E stain, original 
magnification x200). (E) Immunohistochemistry for CD3 shows a normal distribution of 
CD3-positive T-cells in a white pulp nodule (P2, Ventana Benchmark XT 
immunostainer, monoclonal antibody LN10, original magnification x100). (F) 
Immunohistochemistry for CD20 shows a normal distribution of CD20-positive B cells in 
a white pulp nodule (P2, Ventana Benchmark XT immunostainer, monoclonal antibody 
L26, original magnification x100). (G) Congested, disorganized red pulp containing 
increased neutrophils consistent with sepsis (P2, H&E stain, original magnification 
x400). (H) Disorganized reticulin staining pattern of splenic red pulp. Inset: “barrel hoop” 
arrangement of sinusoidal reticulin fibres in a normal control spleen (P2, Gordon and 
Sweet’s reticulin stain, original magnification x400). (I) Immunohistochemistry for CD68 
shows a haphazard arrangement of macrophages in the splenic red pulp. Inset: orderly 
distribution of cordal macrophages in a normal control spleen (P2, Ventana Benchmark 
XT immunostainer, monoclonal antibody PG-M1, original magnification x400). (J) Liver 
showing portal-portal linkage and expansion of portal tracts by a moderate chronic 
inflammatory cell infiltrate without interface activity (P2, H&E stain, original magnification 
x100). (K) Sirius red staining of liver shows collagen deposition (red) within portal-portal 
bridges. Elastin could also be demonstrated (not shown) consistent with established 
portal-portal fibrosis (P2, Sirius red / Fast green stain, original magnification x100). (L) 
Liver showing mild expansion of portal tracts by a chronic inflammatory cell infiltrate but 
no bridging fibrosis (P4, H&E stain, original magnification x200). 
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Figure 10: Histopathology of P2 (A-K, post-mortem, 14 months) and P4 (L, 22 months). 
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Table 3: Clinical features of four patients in the family. 
 
Patient P1 P2 P3 P4 
gender male female female female 
cardiovascular malformation  none none yes 
(pulmonary 
atresia) + 
ventricular 
septal defect 
yes (L-sided SVC 
draining to left 
atrium) 
functional 
hyposplenism 
spleen size NA normal normal normal 
Howell-Jolly bodies NA NA yes yes 
invasive pneumococcal 
infection 
yes 
(meningitis, 4 
mo) 
yes 
(septicemia, 
14 mo) 
no
a 
no
a
features of febrile 
episodes 
documented viral trigger VZV  VZV 
HHV6 
MMR vaccine 
Astrovirus 
Parainfluenza virus 2 
EBV 
encephalopathy yes yes yes yes 
seizures yes yes yes yes 
liver dysfunction 
(maximal ALT, IU/L) 
yes (NA) yes (NA) yes (1042) yes (383) 
ALPS phenotype autoimmune disease no no no no 
presence of 
autoantibodies 
NA NA no
b 
yes
b
 
anti-erythrocyte 
antibodies 
intermittently present 
lymphadenopathy or 
splenomegaly 
no no no no 
% of CD4
-
CD8
-
TCRĮȕ+ T 
cells 
NA NA NA 7.8 
lymphocyte apoptosis NA NA NA impaired 
serum FasL NA NA NA high 
serum IL10 NA NA NA high 
liver histology NA mild chronic 
portal 
inflammation 
with bridging 
fibrosis 
NA mild chronic portal 
inflammation with 
mild fibrosis  
follow-up data  died at 4 mo died at 14 mo died at 4 yr 
and 4 mo. 
alive and currently 2 
yr and 9 mo.  
 
NA, not assessed 
a On antibacterial prophylaxis from early infancy 
b Autoantibody screen including anti-nuclear, anti-smooth muscle, anti-mitochondrial, 
anti-gastric parietal cell antibodies, direct antiglobulin test.  
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Table 4: Whole-Exome sequencing results.  
Total number of reads  24,989,074  
Uniquely Mapped reads  17,816,126  
Total variants called  23,146  
Substitutions  
Total (novela)  21,224 (1796)  
Synonymous  9,936  
Nonsense  71  
Missense  8,121  
SpliceͲsite  37  
NonͲcoding RNAs  58  
Indels  1,922  
dbSNP rateb  91.54%  
dbSNP concordanceb  99.71%  
chromosome 11 region  
Totalc (novela)  67 (8)  
Synonymous (novela) 26 (1)  
Nonsense (novela)  0 (0)  
Missense (novela)  15 (1)  
SpliceͲsite (novela)  0 (0)  
Indels  0  
Chromosome 18 region  
Totalc (novela)  14 (0)  
Synonymous (novela) 6 (0)  
Nonsense (novela)  0 (0)  
Missense (novela)  8 (0)  
SpliceͲsite (novela)  0 (0)  
Indels  0  
 
aNumber of variants not found in dbSNP129, 1000 Genomes and our inͲhouse database 
of 70 exomes.  
bdbSNP rate and concordance are based on dbSNP129. 
cHomozygous variants.  
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CHAPTER 5 
 
 
MUTATION IN NKX2-5 IDENTIFIED IN ONE KINDRED WITH ICA 
 
 
  
49

I was now ready to use WES on the ICA cohort. I thus started to investigate the 
most informative family of the cohort, or at least the one I have the most gDNA samples: 
family B.  
5.1 Identification of a mutation in NKX2-5 in 3 patients from one kindred 
Family B is an African kindred (Family B, Figure 4) with 3 ascertained cases 
(I.1, II.4 and II.5, Figure 11A) and 3 probable cases (II.1, II.2 and II.3, Figure 11A) of 
ICA. I hypothesized that ICA segregated as a fully penetrant, autosomal dominant 
(AD), Mendelian trait in this family. I analyzed the genomic DNA (gDNA) of the 3 
ascertained cases by WES. The number of reads and the exome coverage metrics 
(Table 5) show inferior quality of the assembly for the exome of patient II.4 compared 
to the 2 other patients (42% of target bases covered at 10X compared to 72% and 
71%), likely due to the suboptimal quality of II.4 gDNA, which was extracted from 
necropsy samples. Therefore I selected candidate variations from the annotated data, 
focusing on nucleotide substitutions, insertions or deletions (indels) either present in all 
three patients (I.1, II.4 and II.5), or present in I.1 and II.5 and not covered by WES in 
II.4. The breakdown of the variants identified by WES in each patient is in Table 6. 
After filtering out known polymorphisms reported in the National Center for 
Biotechnology Information (NCBI) dbSNP build 134, the 1,000 Genomes Project 
database (http://www.1000genomes.org), and our own database of 400 exomes at that 
time, I identified only 32 variants that could potentially underlie ICA in this family (Table 
7). 
Strikingly, a substitution in NKX2-5 was one of the 32 candidate variants 
identified. The other 31 variants did not affect genes known to be involved in spleen 
development and/or heterotaxy, whether in humans or in the mouse model (Tables 2 
and 7). The variant identified in NKX2-5 is a missense heterozygous c.707C>A in 
protein-coding exon 2 of NKX2-5 (NM _004387.3, MIM600584) that changes Proline at 
amino acid position 236 to Histidine, p.P236H (referred to as P236H hereafter) (Figure 
11 B, C). I validated this variant by Sanger sequencing of gDNA from peripheral blood 
and of cDNA from EBV-transformed B cells (EBV-B) from ICA patients. This variant 
segregated with ICA in all family members examined, as all patients and none of the 
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healthy relatives were heterozygous for P236H (Figure 11A). The variant was not found 
in 1,052 additional healthy individuals from 52 ethnic groups from the Centre d’Etude du 
Polymorphisme Humain and Human Genome Diversity panels, including 127 samples 
from Sub-Saharan Africa. Moreover, there were 200 samples from Sub-Saharan Africa 
in the 1,197 samples sequenced by the 1,000 Genomes project that we used to filter out 
polymorphisms. Altogether, these results suggest that the P236H variant is a rare and 
possibly ICA-causing variant rather than an irrelevant polymorphism, since it was not 
found in a total of 2,261 control individuals of diverse ethnic backgrounds. Lastly, 
Proline at amino acid position 236 is well-conserved throughout evolution, although an 
Alanine is present at this position in Mus musculus and Rattus norvegicus (Figure 11C). 
Notably, there is no Histidine at this position in any species in which Nkx2-5 has been 
sequenced. In parallel to WES, I examined copy number variants (CNV) in II.5 
throughout the genome, using the Affymetrix 6.0 chip. I did not observe any CNV larger 
than 50 kb that was not present in the DGV database (http://projects.tcag.ca/variation/) 
or our own database of 150 samples. Overall, these genetic data suggested that P236H 
might underly ICA in this multiplex kindred 
5.2 Nkx2-5 is involved in spleen development in the mouse model 
We had already identified NKX2-5 as a candidate gene because one patient with 
a heterozygous frameshift deletion at the N-terminus of NKX2-5 presented both 
congenital heart disease and asplenia104. However it is the work of Matthew Koss, a 
PhD student in the laboratory of Licia Selleri at Cornell Medical School that made this 
result particularly interesting. In the mouse model, Nkx2-5, like Tlx1, is detected in 
E10.5 splenopancreatic mesenchyme and in spleen progenitors thereafter46. 
Nonetheless its role in spleen organogenesis was unclear due to early in utero lethality 
of null mutants105. Different Nkx2-5 partial loss-of-function (LOF) alleles including Nkx2-
5+/- mice105, Nkx2-5Cre/GFP hypomorphic embryos106, and Nkx2-5Y-A:IRESLacZ/+ wild-type 
chimeras, a dominant negative model of Nkx2-5 deficiency conferred by mutation of a 
conserved tyrosine-rich domain107, showed hyposplenia (Figure 12). These mouse 
models demonstrated that Nkx2-5 dosage and mutations in different parts of the protein 
yield spleen hypoplasia. It was thus interesting to look whether the mutation identified in 
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NKX2-5 in patients from family B had an impact on the protein or its function and could 
be disease-causing.  
5.3 Functional characterization of the NKX2-5 mutation 
Because POLYphen II108 predicted that the P236H mutation is benign and 
residue 236 is outside the homeodomain of NKX2-5, we hypothesized that the 
mutation may not impair the production of the protein or its binding to DNA. Indeed, 
Western blot analysis and EMSA assays confirmed that NKX2-5 P236H is normally 
produced and binds to DNA similarly to WT protein46. Instead, we hypothesized that 
the mutation may disrupt transactivation by NKX2-5 likely through interaction with 
essential spleen-specific cofactors. Notably, P236 lies immediately adjacent to the first 
of nine Tyrosines that define a conserved Tyrosine-rich domain (YRD; residues 237-
275) within NKX2-5 (Figure 11C), which previous work of our collaborators established 
as a critical domain for its in vivo function, as well as transcriptional activity in a 
heterologous context107. Significantly, mouse chimeras composed partly of mutant cells 
in which critical Tyrosines in the Nkx2-5 YRD have been replaced by Alanines107, 
develop hypoplastic spleens (Figure 12F). Thus, we posited that the P236H mutation 
could impact the function of the YRD, potentially affecting the interaction of NKX2-5 
with splenic cofactors. 
In order to test the effects of the P236H mutation on the transactivation potential 
of Nkx2-5, we employed a heterologous system that we previously used to study Nkx2-
5 function in mouse heart development107. The C-terminal domain of human NKX2-5, 
containing either the WT or the mutant sequence, was fused to the Gal4 DNA-binding 
domain (DBD), and co-transfected into HEK293T cells with a Luc reporter (pGL4.31) 
downstream of multiple UAS elements. While the WT construct induced an increase in 
Luc expression of about 30-fold versus control, the construct bearing the P236H 
mutation induced significantly lower expression (about one-third of WT) (Figure 13A). 
Notably, mouse constructs bearing mutations of critical Tyrosines within the YRD 
domain showed low activity in this assay, consistent with our previous report107. 
Additionally, since Nkx2-5 is subject to autoregulation in heart development106, we 
tested whether the murine Nkx2-5 spleen and stomach enhancer46 could be 
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transactivated in spleen mesenchyme by full-length WT and/or mutant NKX2-5. We 
transfected SPCL2 cells, a cell line derived from embryonic mouse spleen, with 
expression vectors for WT or P236H NKX2-5, with or without Tlx1, which plays critical 
role in mouse spleen development as mentioned earlier57. NKX2-5 WT co-transfected 
with Tlx1 activated the Nkx2-5 Luc reporter approximately 2.5-fold above control, 
whereas this transactivation was abolished when using the mutant NKX2-5 P236H 
(Figure 13B). The same Nkx2-5/Tlx1 co-transfection experiment performed with 
HEK293T cells did not lead to activation of the Nkx2-5 Luc reporter, highlighting that 
this co-operative transactivation of Nkx2-5, as well as its requirement for P236, are 
spleen-specific. Altogether, these results demonstrated that the P236H mutation 
impairs transactivation by NKX2-5, both in a heterologous transactivation assay and in 
the context of spleen mesenchymal progenitors. Given the findings in our mouse 
models, in which reduced Nkx2-5 gene dosage or YRD function yield hyposplenia, and 
the observed functional deficiency of the NKX2-5 P236H mutation identified in ICA 
patients, we concluded that Nkx2-5 plays a central role in the development and growth 
of the spleen in mice and likely in humans. 
The basic knowledge acquired in the mouse has helped define the etiology of 
ICA in one kindred. Indeed, Pbx target genes identified in the mouse spleen anlage in 
the study done in the laboratory of Licia Selleri guided the analysis of WES. This 
approach led to the identification of a novel missense mutation in NKX2-5, which is a 
central component within the Pbx-directed module in the mouse. This novel NKX2-5 
variant segregates with ICA in all family members examined, and it is not present as a 
polymorphism in large and diverse human populations, including Sub-Saharan ethnic 
groups. Notably, the P236H mutation significantly diminished transactivation by Nkx2-5 
in both a heterologous transcriptional assay and in cultured spleen cells. In the latter 
assay, transactivation occurs only in the presence of the spleen-specific cofactor Tlx1, 
suggesting that in this context spleen-specific interactions are disrupted by the P236H 
mutation. Interestingly, all known congenital heart disease (CHD) patients with 
previously-identified NKX2-5 mutations do not display asplenia (Harvey et al., 2002), 
indicating that the P236H mutation would preferentially compromise spleen 
development. Moreover the subsequent Sanger sequencing of all exons of NKX2-5 in 
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all other ICA patients of our cohort did not lead to the identification of another novel 
mutation in this gene. Together these results suggested that a mutation in NKX2-5 
might lead to ICA in humans but that other mutations in at least one other gene were 
likely to be the major genetic etiology of ICA. 
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Figure 11: Genetics of an inherited NKX2-5 Mutation in ICA patients. 
(A) Pedigree of the family. Black symbols indicate ICA cases. Gray symbols indicate 
siblings who died early in childhood with clinical symptoms similar to those of II.4. 
Haplotypes of NKX2-5 are indicated: M stands for c.707C>A, WT for wild-type allele, 
E? for unknown haplotype. (B) Illumina sequencing reads displayed for patient I.1. 
Reads are reversed. Reads overlap the mutation in exon 2 of NKX2-5 (bp position 
g.172,659,827 – g.172,659,852 , hg19). (C) Schematic diagram of the NKX2-5 protein 
(drawn to scale) showing conserved and/or functional domains (homeodomain: HD; 
tinman/Nkx2-5 domain: TN; NK2 specific domain: NK; tyrosine rich domain: YRD). Two 
other conserved domains, the NKX2-5 box and the GIRAW motif, are indicated by 
yellow and green boxes, respectively. Evolutionary conservation of the NKX2-5 region 
containing amino acid P236 is represented below. 
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Figure 11: Genetics of an inherited NKX2-5 Mutation in ICA patients. 
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Figure 12: Reduced Nkx2-5 levels lead to hyposplenia in the mouse model. 
(A-D) Reduced Nkx2-5 levels in Nkx2-5+/- (B), and Nkx2-5Cre/GFP (D) mice result in 
smaller spleens versus controls (A and C: P0 and E17.5). (E-F) Depicted are spleens 
taken from Nkx2-5Y-A:IRESlacZ/+lwildtype chimaeric mouse pups at P0106. Chimaeric 
spleens (right panel), with reduced Nkx2-5 function, are smaller and dismorphic, 
compared to WT (left panel). 
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Figure 12: Reduced Nkx2-5 levels lead to hyposplenia in the mouse model. 
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Figure 13: P236H mutation impairs NKX2-5 functional activity. 
(A) HEK293T cells are transfected with a UAS-Luc reporter and different expression 
vectors consisting of the Gal4 DNA-binding domain fused to the C-terminus of human 
NKX2-5. NKX2-5 WT: WT NKX2-5 C-terminus. NKX2-5 P236H: the C-terminus of 
NKX2-5 with the P236H mutation. NKX2-5 Y->A and NKX2-5 Y->F: fusion constructs in 
which all Tyrosines in the YRD have been substituted with Alanines or Phenylalanines 
respectively107, used as negative controls. Data represent average from two 
independent experiments.  Error bars indicate S.E.M. (B) SPCL2 cells are transiently 
transfected and co-transfected with Tlx1 expression vector, a Luc reporter containing 
the Nkx2-5 spleen-stomach enhancer (pGL3-Nkx2-5-Luc) and different human NKX2-5 
expression vectors. Data represent average from four independent experiments. Error 
bars ± S.E.M. 
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Figure 13: P236H mutation impairs NKX2-5 functional activity. 
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Table 5: Exome sequence alignment and coverage data for family B. 
Metric I.1 II.5 II.4 Legend
Genomesize 3,095,677,412 3,095,677,412 3,095,677,412
Thenumberofbasesinthe
referencegenomeusedfor
alignment
Baitterritory 38,925,418 38,925,418 38,925,418
Thenumberofbaseswhich
haveoneormorebaitsontop
ofthem
Totalreads 40,784,315 37,764,604 38,145,467 Thetotalnumberofreadsinthe
SAMorBAMfileexamine
PFunique
reads 35,608,020 33,530,320 31,969,422
Thenumberofreadsthatare
notmarkedasduplicatesand
passedqualityfilters(PF)
Ontarget
bases 870,807,186 791,839,532 372,842,179
ThenumberofPFalignedbases
thatmappedtoatargetted
regionofthegenome
Meantarget
coverage 23.13 20.95 9.98
Themeancoverageoftargets
thatrecievedatleastcoverage
depth=2atonebase
Pcttarget
bases2X 92 93 86
ThepercentageofALLtarget
basesacheiving2Xorgreater
coverage
Pcttarget
bases10X 72 71 42
ThepercentageofALLtarget
basesacheiving10Xorgreater
coverage
Pcttarget
bases20X 48 43 12
ThepercentageofALLtarget
basesacheiving20Xorgreater
coverage
Pcttarget
bases30X 29 23 2
ThepercentageofALLtarget
basesacheiving30Xorgreater
coverage

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Table 6: Breakdown of variants identified by WES of 3 patients from family B. 
Variants  I.1 II.5 II.4 I.1 & 
II.5 
I.1 & II.5
- 
dbSNP5 
I.1 & II.5 
- dbSNP  
 - 1k genomes6 
I.1 & II.5
Novel7 
I.1 & II.4 
& II.5 
Novel8 
TOTAL 1 24,630 25,009 17,956 16,881 484 184 101 48 
Substitutions 23,932 24,367 17,541 16,480 415 162 97 47 
Synonymous 10,116 10,402 7,955 7,296 109 21 18 7 
Nonsense2 104 103 74 71 9 3 1 0 
Missense 8,849 8,975 6,923 6,261 217 54 44 24 
Splice-site3 2,240 2,268 1,594 1,526 49 40 15 8 
Non-coding 
RNAs 
262 230 186 139 7 3 1 0 
UTRs 3,086 3,122 1,379 1,690 54 41 18 9 
         
Indels4 698 642 415 401 69 22 4 1 
1: Heterozygous or homozygous variations are included. Variations that mapped in 
intergenic, or intronic regions that were not ranked as splice-site regions were excluded.  
2: All variations leading a stop gain or a start/stop loss were included in this category. 
3: All variations within 1-3 bp into exon or 1-8 bp into intron.  
4: Frameshift and non-frameshift insertions or deletions are included.  
5: Not found in the NCBI dbSNP build 134.  
6: Not found in the dbSNP 134 or in the last release of the 1,000 genomes project (July 
2011) including 1,197 whole genomes.  
7: Not found in our in-house database of 400 exomes or in the dbSNP 134 or in the last 
release of the 1,000 genomes project.  
8: Novel variants identified in I.1, II.5 and II.4 or I.1, II.5 and with 2 or less reads at this 
position for II.4.  
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Table 7: List of non-reported variations shared by I.1, II.4 and II.5 
Chr.
Position
(hg19build) Allele Gene Accessionno. Functionalimpact
1 24417388 C/T MYOM3 NM_152372.3 Missense(p.R444Q)
1 226555934 T/C PARP1 NM_001618.3 Missense(p.K748R)
2 196791265 T/C DNAH7 NM_018897.2 Missense(p.Y1166C)
3 52823663 T/C ITIH1 NM_0022152.2 Splicing
3 65365233 T/C AC121493.1 NM_001033057.1 Splicing
3 119133310 A/T ARHGAP31 NM_020754.2 Missense(p.D845V)
4 190947127 A/C FRG2 NM_001005217.1 Missense(p.D142E)
5 9054321 G/C SEMA5A NM_003966.2 Missense(p.T856R)
5 112227446 G/A ZRSR1 ENST00000391338 Missense(p.R37Q)
5 115336788 A/T AC034236.1 NM_173800.4 Missense(p.I558F)
5 128302174 A/G SLC27A6 NM_014031.3 Missense(p.E115G)
5 172659840 G/T NKX2Ͳ5 NM_004387.2 Missense(p.P236H)
6 26468409 A/G BTN2A1 NM_007049.2 Missense(p.S406G)
6 40400032 C/T LRFN2 NM_020737.1 Missense(p.R274H)
6 42626002 A/T UBR2 NM_015255.1 Missense(p.R1003W)
8 141675010 C/T PTK2 NM_005607.3 Splicing
9 114825283 G/A SUSD1 NM_022486.3 Missense(p.T595M)
10 95072806 C/A MYOF NM_133337.2 Missense(p.A1941S)
10 105815761 G/A COL17A1 NM_000494.3
Missense(p.A489V)and
Splicing
11 3111787 C/T OSBPL5 NM_020696.3 Splicing
11 17191035 T/C PIK3C2A NM_002645.2 Missense(p.K85R)
11 123813978 C/T OR6T1 NM_001005187.1 Missense(p.G190R)
12 82750746 T/C CCDC59 NM_014167.3 Missense(p.T153A)
13 46425657 AC/TA SIAH3 NM_198849.2 Missense(p.C36L)
14 21109553 T/C OR6S1 NM_001001968.1 Missense(p.I100V)
14 65209852 G/A PLEKHG3 NM_015549.1 Missense(p.G975S)
15 74554773 C/T CCDC33 NM_025055.3 Splicing
16 1995622 G/T RPL3L NM_005061.2 Splicing
17 5085443 ACT/Ͳ ZNF594 NM_032530.1 DeletionS703
17 27861129 G/C TAOK1 NM_020791.1 Splicing
19 2111779 G/A AP3D1 NM_003938.5 Missense(p.R884W)
22 50705585 C/T MAPK11 NM_002751.5 Missense(p.V156M)
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CHAPTER 6 
 
 
HAPLOINSUFFICIENCY OF RPSA CAUSES ICA 
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6.1 Sequencing of all the exomes of the cohort 
We thus sequenced 28 additional exomes for all the patients in our cohort for 
whom we had enough gDNA (Figure 4). In total we had the exome of 31 patients. The 
first 16 exomes (3 of them from family B) were sequenced with the Agilent Human All 
Exon 38Mb kit. The remaining exomes were sequenced using the newer kit: the 50Mb 
kit. Because all the patients shared the same clinical phenotype, we hypothesized that 
different mutations in one other gene than NKX2-5 would be disease-causing in at least 
two kindreds. We thus compared and analyzed the sequencing data of all the exomes 
(n=31) together and looked for candidate disease-causing genes mutated in multiple 
patients. Firstly, we decided to analyze all the patients as if they were unrelated 
because the number of reads and coverage metrics for each exome highlighted a 
significant difference of quality between the two Agilent kits (Table 8), as well as a lower 
quality for the two patients for whom gDNA was obtained from necropsy samples 
(patient JL77 and JL423, Figure 4). Therefore the WES might pick up a variation in one 
member of one kindred and not the other one simply because the coverage was not 
identical in the 2 exomes. This is why we decided not to consider any relationship 
between samples at first. Secondly, due to the severity of the phenotype and the rarity 
of ICA, about 1/1,000,000 births15, we hypothesized that the disease-causing variants 
would have an impact at the protein level and would not be common polymorphisms. 
Any polymorphism with a frequency >0.1% would not fit with the frequency of the 
disease, even with an AR mode of inheritance, if we hypothesize that the penetrance of 
the trait is high. Therefore we filtered out all variants that were present in the NCBI 
dbSNP 134 database, or in the database of the 1000 genomes project, or in our in-
house database of 1000 exomes. We also filtered out the variants that were intronic, 
located in the untranslated regions or synonymous and were not in essential splice 
sites. Finally we crossed the results of the 31 exomes and looked at genes carrying 
novel variants in more than one patient. Fourteen genes were mutated in more than 6 
patients (Table 9).  
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6.2 Identification of heterozygous mutations in RPSA 
Some genes, in particular the very big genes, have statistically more chance to 
carry novel variations. Therefore we wanted to test if the high number of variations 
observed in RPSA (MIM #150370) or TTN (MIM #188840) were statistically significant. 
Ideally we would need to compare the number of novel variants in one gene in our 
cohort and the number of novel variants in the same gene in a control cohort. As a test 
experiment, I performed the exact same analysis I did for the ICA patients on exomes 
from 6 other projects in the laboratory. I selected projects of a similar sample size and 
projects where the patients do not present any invasive pneumococcal disease as some 
of these might present an undiagnosed ICA. Strikingly, the majority of the genes 
frequently mutated in ICA were also frequently mutated in the other projects confirming 
the bias for some genes (Table 9). The gene with the highest number of novel 
mutations in the ICA cohort, and that was not frequently mutated in the other cohorts is 
RPSA.  
Even though this analysis validated our hypothesis, a more mathematical and 
systematic method to evaluate the significance of the results was needed. In particular 
for smaller projects, or projects where one gene does not clearly stand out, a method to 
calculate the probablility of one gene to be mutated in X samples among Y samples was 
needed. Iuliana Ionita-Laza from Columbia University developed an algorithm that 
would calculate such probablility109. The algorithm would rank the genes according to 
two main factors. The first factor is the number of novel variations in one gene in the 
‘cases’ exomes. The second factor depends on the number of novel variations in one 
gene in the ‘cases’ exomes vs the number of novel variations in the same gene in the 
‘control’ exomes. The more ‘cases’ and ‘controls’ you have, the more powerful this 
method is. I tried to use this joint-rank approach using 650 exomes from other projects 
in the laboratory as controls (I excluded again all patients suffering from IPD as these 
might have an undiagnosed ICA). The first results did not show anything significant due 
to the high number of false positive variants left in our analysis. I used the raw 
sequencing results to perform this analysis. Therefore variants in introns would also be 
taken into account. Removing these intronic variants in RPSA for our cohort and the 
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control cohort led to a very significant result for RPSA (Figure 14A). However a new 
analysis and new calculations using the algorithm will be done as soon as the raw data 
from the WES are realigned, annotated and the variants called again using a much 
more stringent filter. Given the fact that we now have a large number of samples it is 
probably better to have false negatives, i.e. mutations that are missed because not 
called, rather than false positives, i.e. mutations that are called although they are merely 
alignment errors.   
RPSA being the highest ranked gene in our empirical statistical approach, we 
validated the mutations in RPSA by Sanger sequencing. We then resequenced the 
coding exons of RPSA in all patients. In total 16 patients from 8 kindreds, including the 
patients carrying the mutation in NKX2-5, were mutated in the coding region of RPSA 
(Figure 14B). Not all of the mutations were identified by WES because the coverage of 
RPSA in the 38Mb kit was poor due to the numerous pseudogenes. The advent of 
paired-end sequencing increased the coverage of this gene and enabled the 
identification of mutations in the recently sequenced ones. 7 different mutations, not 
irrelevant polymorphisms, were identified including one nonsense mutation (p.Q9X) and 
one frameshift insertion (p.P199Sfs) (Table 10). The five missense mutations affected 
residues that were conserved in mammals, plants, and prokaryotes (Figure 14C). We 
confirmed that the mutations followed the familial segregation in all kindreds (Figure 
14B). Strikingly the mutations appeared de novo in the 2 sporadic cases, and the 
p.T54N mutation probably resulted from germline mosaicism from the father or the 
mother in kindred F. Microsatellite analysis, or HLA typing confirmed familial 
segregation in these families. Taken together these results strongly suggest that 
heterozygous mutations in RPSA lead to ICA in humans, with a complete penetrance, 
and in an autosomal dominant way. 
6.3 The combination of non-coding mutations in RPSA leads to ICA in two 
multiplex families 
We continued our genetic dissection of ICA by searching for non-coding 
mutations in RPSA in the patients not yet mutated in this gene. We hypothesized that 
novel mutations (i.e. not reported and not found in controls) in the 5’-UTR, 3’-UTR, 
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introns or promoter region of RPSA might lead to ICA. Sanger sequencing of these 
regions led to the identification of two novel non-coding mutations. One mutation is a 
substitution of a C to a T in the 5’-UTR (c.-48C>T, 3:39448242) in one family with one 
ICA patient and a possible ICA patient. The other novel non-coding mutation identified 
is a substitution in the intron 5 base pairs after exon 1, c.-35+5G>C (Table 11, Figure 
15A). This position is at the donor site and might affect the splicing of exon 1.These two 
mutations were not found in any database. For example they were not reported in the 
1000 genomes browser on 09/02/2012. None of the 2178 samples sequenced carried 
these mutations. These mutations were confirmed by Sanger sequencing and the other 
family members were sequenced. Familial segregation revealed that one healthy 
individual carried the splice mutation whereas two healthy individuals carried the 
substitution in the 5’-UTR (Figure 15B).  
All patients carrying a heterozygous coding mutation in RPSA presented the 
disease (complete penetrance) (Figure 14B), indicating that environmental factors had 
a small impact on the onset of the disease, at least in the individuals mutated in RPSA. 
Therefore we hypothesized that a modifier variation or polymorphism in RPSA might be 
required in addition to the non-coding mutations to lead to ICA in patients from families 
G and H. In other words these non-coding mutations might reduce the function or 
expression of RPSA by 40%, which would not be disease-causing. However if there is 
another polymorphism that might reduce the expression of RPSA by 10%, the addition 
of these two variants would be disease-causing. We thus sequenced and listed all the 
polymorphic variants of RPSA in all members of family G and H. Strikingly the 20bp 
deletion (rs139686560 or rs199844419) upstream of exon 1 of RPSA segregates well 
with the disease when combined with the splice mutation or the 5’-UTR mutation 
(Figure 15B). Moreover the frequency of this 20bp deletion is 0.006 (13/2178) 
according to the 1000 Genomes browser 
(www.ncbi.nlm.nih.gov/variation/tools/1000genomes/). This frequency is too high for the 
deletion to be ICA-causing alone but is low enough that it could play a role in the 
disease.    
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Finally the mutations need to have an impact on RPSA either at the mRNA level 
or the protein level in order to be disease-causing. We first tested the impact of the 
splice mutant. We extracted mRNA from EBV-B cells from the members of family G, 
made cDNA and sequenced it. The sequences reveal the presence of a splice variant at 
the mRNA level (Figure 15C). This variant has an extra 43bp at the end of exon1. The 
intensity of the peaks suggests that about 40% of the isoforms of RPSA in the patients 
from family G have this extra 43bp in the 5’-UTR. However a precise quantitation needs 
to be done using the TA cloning technique. Deciphering the impact of these extra 43bp 
in the middle of the 5’-UTR, as well as the impact of the 20bp deletion upstream the 5’-
UTR, and the impact of the mutation in the 5’-UTR in family H will be necessary. They 
might also give more insights in the pathogenesis of ICA. All together we identified 
novel mutations in RPSA in 19 ICA patients from 10 unrelated kindreds (Figure 16). 
This represents 57% of the ICA patients for whom we had gDNA and therefore we could 
sequence RPSA. Assuming we had gDNA for all the possible cases in gray and that the 
possible cases in families where the ascertained cases are mutated in RPSA would be 
mutated in RPSA, then we could have 30 out of 44 ICA patients mutated in RPSA 
(Figure 16). These results show that RPSA is the major disease-causing gene of ICA in 
humans.  
6.4 Haploinsufficiency of RPSA leads to ICA 
To go further in the genetic dissection of ICA, we asked whether the mutations in 
RPSA led to ICA by haploinsufficiency or dominance negative effect. We did not have 
access to cells from patients with the p.Q9X mutation, but we had blood samples from 
the patients carrying the frameshift mutation p.P199Sfs. Sequencing the cDNA from 
RNA extracted from PBMCs of these patients did not reveal any mutation (Figure 17). 
This highlights the fact that the mutated allele is degraded, most likely through 
nonsense-mediated mRNA decay, and only one copy of RPSA is present at the mRNA 
level in patients from family C. These results suggest that haploinsufficiency of RPSA 
leads to ICA in at least one family. The diversity of the mutations, as well as the fact that 
non-coding mutations affecting about half of the RPSA transcripts also lead to ICA 
suggest that haploinsufficiency of RPSA leads to ICA in the majority of the families.    
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Therefore we hypothesized that a large deletion, encompassing the entire gene, 
or some exons of RPSA, might lead to ICA. Since large deletions cannot be detected by 
WES, we used the Multiplex Ligation-dependent Probe Amplification (MLPA) method110 
and assessed the copy number of RPSA in 16 patients and in 15 controls. One patient 
from family G, as well as one patient from family H were included and used as controls. 
One probe upstream of each exon of RPSA was designed in addition to four control 
probes. No deletion or copy number was identified at the RPSA locus except for the 
loss of one copy of the probe upstream of exon 1 in the two patients from family G and 
H (Figure 18). This result was expected as the probe upstream of exon 1 overlapped 
with the 20bp deletion described above and identified in these two patients. We can 
conclude that no large deletion in the RPSA locus causes ICA in the patients of our 
cohort.  
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Figure 14: WES identifies mutations in RPSA in ICA patients. 
(A) Manhattan plot representing the p-values (P) for 21,185 genes. P-values were 
calculated by a weighted sum approach, comparing novel variants identified by WES in 
30 cases and 593 controls. (B) Pedigrees of all the kindreds carrying coding mutations 
in RPSA. Black symbols indicate ICA cases. Gray symbols indicate possible ICA 
patients. WT means wiltd-type allele. M represents the mutated allele. (C) Schematic 
diagram of the RPSA protein (drawn to scale) showing the different parts encoded by 
different exons. Mutations identified in ICA patients are marked in red. Evolutionary 
conservation of the RPSA regions containing amino acids mutated in ICA patients are 
represented below. 
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Figure 14: WES identifies mutations in RPSA in ICA patients. 
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Figure 15: Non-coding mutations in RPSA. 
(A) Schematic of the RPSA gene. Exons are represented by rectangles and introns by a 
line. Smaller rectangles indicate the untranslated regions. Size of introns and exons are 
at scale. Below the scheme is a zoom of the C-terminal part of exon 1. The blue 
rectangle represents the end of exon 1. Above the rectangle, letters indicate the base 
pairs. Below the two non-coding mutations are indicated. (B) Pedigrees of family G and 
H indicating the genotypes for the mutation in the 5’-UTR (family H) and the genotypes 
for the splice variant (family G). Genotypes for the 20bp deletion upstream of exon 1 
(rs139686560) are also indicated. Black symbols represent ICA patients. Gray symbols 
indicate possible ICA patients. (C) Scheme of the WT transcript of RPSA and of the 
spliced variant transcript. The red rectangle represents the extra 43bp added in the 5’-
UTR (corresponding to the first 43bp of the intron between exons 1 and 2. 
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Figure 15: Non-coding mutations in RPSA. 
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Figure 16: More than 50% of the ICA patients are mutated in RPSA. 
Black symbols indicate ICA patients. Gray symbols indicate possible ICA patients. 
Pedigrees circled in red indicate families carrying mutations in RPSA. 
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Figure 16: More than 50% of the ICA patients are mutated in RPSA. 
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Figure 17: Haploinsufficiency of RPSA in one ICA patient. 
Automated sequencing profile. The two top profiles correspond to the sequencing of the 
gDNA of patient I.2 in family C (mother) and shows heterozygous peaks due to the 
heterozygous insertion of 5 bp (TCATG). The two rows correspond to the sequencing 
using a forward or reverse primer. The two profiles on the bottom correspond to the 
sequencing of the cDNA of patient I.2 in family C. No heterozygous peaks are apparent, 
showing that the allele carrying the insertion is not present at the mRNA level.  
These profiles are illustrative of three independent experiments where the gDNA and 
cDNA of the two patients and the healthy father were extracted from PBMCs or ficoll, 
and later amplifie and sequenced using different pairs of primers around the insertion. 
Primers for the gDNA bind in the introns around exon 5. Primers for the cDNA bind to 
the coding region of RPSA. DNAse treatment was performed before amplification and 
RT negative controls did not show any sequence. 
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Figure 17: Haploinsufficiency of RPSA in one ICA patient. 
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Figure 18: MLPA results showing deletion of one copy of probe R1. 
Example of the fragment analysis results after MLPA method in one control, G-I.1 
(father in family G), and one ICA patient, G-II.2 (JL0425 in family G). Horizontal axis 
represents the size of each probe. Vertical axis represents the intensity of the peaks. 
Each probe is represented by one peak. Control probes: X, 18, Y and IF hybridize in 
BCAP31, SS18, SRY and IFNȖ respectively. Probes in RPSA are represented by R1, 
R2, R3, R4, R5, and R7. In red R1 is decreased compared to the other peaks in the 
patients’ sample. 
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Figure 18: MLPA results showing deletion of one copy of probe R1. 
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Table 8: Metrics and coverage for the 31 exomes of the ICA cohort. 
Sample JL0023 JL0074 JL0075 JL0076 JL0077 
Single/Paired-end single-end single-end single-end single-end single-end 
Bait set 38mb 38mb 38mb 38mb 38mb 
Total reads 17,236,982 46,309,265 40,784,315 37,764,604 38,145,467 
PF uq reads aligned 10,107,021 21,996,482 20,089,344 17,806,372 7,410,366 
PF uq bases aligned 768,010,436 1,759,448,314 1,606,927,209 1,424,306,381 592,624,602 
Mean bait coverage 14.295475 24.739707 22.371171 20.34248 9.578373 
Pct target bases 2X 0.909743 0.924441 0.918023 0.93181 0.860445 
Pct target bases 10X 0.590847 0.750323 0.722219 0.712834 0.421068 
Pct target bases 20X 0.268231 0.530087 0.484732 0.428057 0.115878 
Pct target bases 30X 0.104084 0.342634 0.293734 0.234513 0.023321 
 
Sample JL0078 JL0079 JL0080 JL0081 JL0082 
Single/Paired-end paired-end single-end single-end single-end single-end 
Bait set 50mb 50mb 50mb 50mb 50mb 
Total reads 107,126,412 40,420,470 43,328,673 41,294,667 83,706,065
PF uq reads aligned 84,546,171 25,184,279 25,840,648 25,465,508 39,537,580
PF uq bases aligned 8,485,940,747 1,913,831,850 1,963,698,167 1,935,215,309 3,992,605,795
Mean bait coverage 67.418656 22.723002 23.597151 22.862263 45.813742
Pct target bases 2X 0.960521 0.909346 0.909479 0.908707 0.938292
Pct target bases 10X 0.902727 0.741285 0.745674 0.738741 0.855381
Pct target bases 20X 0.840115 0.507457 0.523226 0.507219 0.758379
Pct target bases 30X 0.7673 0.299268 0.320089 0.302696 0.647906
 
Sample JL0083 JL0084 JL0085 JL0086 JL0087 
Single/Paired-end single-end single-end single-end single-end single-end 
Bait set 50mb 50mb 50mb 50mb 50mb 
Total reads 78,783,938 31,199,061 32,809,507 30,654,762 40,377,837
PF uq reads aligned 37,235,703 18,972,448 20,448,833 18,669,724 23,842,750
PF uq bases aligned 3,760,154,743 1,441,770,850 1,553,960,059 1,418,746,611 1,811,876,919
Mean bait coverage 43.565747 16.629181 18.20785 17.181194 20.917354
Pct target bases 2X 0.933597 0.892851 0.899239 0.902562 0.901283
Pct target bases 10X 0.84679 0.65101 0.679147 0.667414 0.710284
Pct target bases 20X 0.743303 0.342122 0.389697 0.353665 0.462034
Pct target bases 30X 0.625841 0.153176 0.190392 0.161803 0.259161

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Sample JL0236 JL0420 JL0421 JL0424 JL0425 
Single/Paired-end paired-end paired-end paired-end paired-end paired-end 
Bait set 50mb 50mb 50mb 50mb 50mb 
Total reads 125,029,032 117,243,000 140,492,902 103,098,554 85,285,190
PF uq reads aligned 110,617,562 98,100,474 121,287,351 91,843,102 75,544,358
PF uq bases aligned 11,081,506,521 9,816,627,457 12,141,343,988 9,226,836,010 7,591,196,405
Mean bait coverage 84.436359 72.119993 81.998927 63.497999 54.41728
Pct target bases 2X 0.969456 0.928401 0.965584 0.959868 0.957073
Pct target bases 10X 0.926532 0.837049 0.910576 0.88943 0.877033
Pct target bases 20X 0.875383 0.745354 0.850711 0.809445 0.780905
Pct target bases 30X 0.818594 0.657251 0.787337 0.717467 0.668404
 
Sample JL0426 JL0427 JL0428 JL0429 JL0430 
Single/Paired-end paired-end paired-end paired-end paired-end paired-end 
Bait set 50mb 50mb 50mb 50mb 50mb 
Total reads 45,334,202 89,145,496 124,471,982 102,668,730 124,254,726
PF uq reads aligned 40,233,025 79,459,443 105,828,597 89,271,170 110,269,877
PF uq bases aligned 4,040,271,697 7,982,074,597 10,595,467,142 8,954,595,385 11,071,632,524
Mean bait coverage 30.19325 54.872578 77.966611 63.012581 71.986333
Pct target bases 2X 0.933296 0.953551 0.931559 0.959286 0.963892
Pct target bases 10X 0.794005 0.872634 0.84806 0.886683 0.900822
Pct target bases 20X 0.594626 0.778277 0.764386 0.805487 0.830957
Pct target bases 30X 0.404496 0.669789 0.682501 0.713138 0.753709
 
Sample JL0431 JL0432 JL0433 JL0434 JL0627 
Single/Paired-end paired-end paired-end paired-end paired-end paired-end 
Bait set 50mb 50mb 50mb 50mb 50mb 
Total reads 109,856,484 79,120,912 98,829,284 72,651,514 21,841,098
PF uq reads aligned 95,581,558 69,749,207 87,207,926 63,845,042 20,931,942
PF uq bases aligned 9,539,384,937 6,998,934,247 8,744,717,784 6,410,188,375 2,101,848,864
Mean bait coverage 67.133081 49.687267 59.470436 45.48222 11.575381
Pct target bases 2X 0.942637 0.950422 0.955405 0.950631 0.842905
Pct target bases 10X 0.852382 0.855911 0.877213 0.853847 0.432141
Pct target bases 20X 0.760625 0.74382 0.789479 0.731924 0.173824
Pct target bases 30X 0.673637 0.620407 0.689303 0.59457 0.076029

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Sample JL0628 Legend
Single/Paired-end paired-end  
Bait set 50mb  
Total reads 61,441,428 The total number of reads in the SAM or BAM file examine
PF uq reads aligned 
58,012,862 
The number of PF unique reads that are aligned with mapping 
score >0 to the reference genome
PF uq bases aligned 5,787,492,782  
Mean bait coverage 31.352339 The mean coverage of all baits in the experiments 
Pct target bases 2X 
0.918495 
The percentage of ALL target bases achieving 2X or greater 
coverage. 
Pct target bases 10X 
0.755845 
The percentage of ALL target bases achieving 10X or greater 
coverage. 
Pct target bases 20X 
0.543446 
The percentage of ALL target bases achieving 20X or greater 
coverage. 
Pct target bases 30X 
0.379732 
The percentage of ALL target bases achieving 30X or greater 
coverage. 
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Table 9: Genes mutated in six or more ICA patients after analysis of 31 exomes. 
Gene #patients
mutated
#novel
mutations
Significant
1
TTN 15 18 No
MUC4 14 20 No
CUBN 9 8 No
NEB 8 8 No
MUC5B 7 11 No
FRAS1 7 6 No
RPSA 7 5 Yes
IGHV2Ͳ70 6 13 No
USH2A 6 8 No
KIAA0284 6 6 No
FBN3 6 6 No
MUC16 6 6 No
ANK2 6 4 No
OSBPL5 6 3 Yes

1: In this case, a gene is called significant if the gene was not mutated in more than 3 
patients in one other project of a similar size (between 20 to 45 samples) from the 
laboratory using the exact same filters. Projects included were: HSE, MSMD, TB, CMC, 
Flu and Whipple. Projects where patients are susceptible to IPD were not included. The 
analysis was done in December 2011.  
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Table 10: Summary of all coding mutations in RPSA. 
Family Ethnic
origin
(countryof
residence)
Position
(hg19build)
Mutation Proteinimpact De
novo

SIFT(score)1 PolyphenͲ2
HumDiv
(score)
2
PolyphenͲ2
HumVar
(score)
2
E Caucasian
(USA)
3:39,449,169 c.25C>T p.Gln9X
Q9X
N/A N/A N/A N/A
F Caucasian
(France)
3:39,450,124 c.161C>A p.Thr54Asn
T54N
Yes* DAMAGING
(0)
BENIGN
(0.147)
BENIGN
(0.433)
O Caucasian
(France)
3:39,450,135 c.172C>T p.Leu58Phe
L58F
Yes DAMAGING
(0.01)
BENIGN
(0.167)
BENIGN
(0.257)
T Caucasian
(Sweden)
3:39,453,179

c.538C>T p.Arg180Trp
R180W
Yes DAMAGING
(0.02)
POSSIBLY
DAMAGING
(0.479)
BENIGN
(0.081)
D Caucasian
(Italy)
3:39,453,179

c.538C>G p.Arg180Gly
R180G
N/A DAMAGING
(0.02)
BENIGN
(0.390)
POSSIBLY
DAMAGING
(0.579)
A Caucasian
(UK)
3:39,453,179

c.538C>G p.Arg180Gly
R180G
N/A DAMAGING
(0.02)
BENIGN
(0.390)
POSSIBLY
DAMAGING
(0.579)
B Subsaharan
Africa
(CongoͲ
Brazaville)
3:39453197

c.555C>T p.Arg186Cys
R186C
N/A DAMAGING
(0.03)
BENIGN
(0.003)
BENIGN
(0.009)
C Caucasian
(France)
3:39453230

c.589_593
dup
p.Pro199SerfsX26
P199Sfs
N/A N/A N/A N/A

1: SIFT score were calculated on http://sift.jcvi.org/ on 09/02/2012. 
2: Polyphen scores were calculated on http://genetis.bwh.harvard.edu/pph2 on 
09/02/2012 

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CHAPTER 7 
 
 
RPSA IN THE DEVELOPMENT OF THE SPLEEN 
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RPSA also called laminin receptor 1 (LAMR) encodes for ribosomal protein SA. 
In yeast the homolog of RPSA is RPS0, and it is RPS2 in prokaryotes. RPSA is 
ubiquitously expressed and has never been associated with the development of the 
spleen46; 111. In order to understand the mechanism of disease or to link RPSA with the 
spleen, we could tackle the problem from two sides: at the molecular scale or at the 
organism scale.  
7.1 Clinical details of human RPSA haploinsufficiency 
We started to look at the human level. We asked if there was any specific 
phenotype shared by the patients carrying RPSA mutations. Was there a phenotype we 
had not noticed, or was there a phenotype that was present in these samples and not in 
the other ICA patients of our cohort that were not carrying an identified RPSA mutation? 
Extensive case reports were sent by the physicians from these ten kindreds and are 
summarized in table 11. These data confirmed that the patients had no phenotype 
outside the spleen. They had no heart malformations as expected. Moreover complete 
blood counts from all patients and some of their siblings confirmed that the patients had 
no hematologic phenotype. None had anemia.  
On the other hand, it was striking that the four post mortem analyses from 4 
unrelated patients carrying 4 different mutations in RPSA and followed by four different 
physicians described the same spleen phenotype (Table 11). The spleen was 
minuscule and a large part of the spleen was a fibrotic nodule. At the periphery of the 
fibrotic nodule there was hemosiderin deposition (or presence of Gandy-Gamna bodies 
depending on the reports) whereas the remaining parenchyma was mostly red pulp with 
very few lymphoid follicles (Figure 19). The pathologists saw the sign of a hemorrhagic 
infarct of the spleen. A late infarction of the spleen might explain why some patients 
were only diagnosed at adult age and did not suffer any severe infections in childhood. 
The other possibility to explain these adult-diagnosed patients could merely be a bias 
from our recruitment. However, some patients were diagnosed as early as 3 days old 
(Table 11). This would mean that the infarct happened prenatally, which is unlikely. 
Therefore two hypotheses seem possible. The pathologists suggest that the spleen 
developed normally and suddenly infarcted. The non-pathologists suggest the spleen 
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never developed properly and this led to this small characteristic spleen of patients 
mutated in RPSA.  
One way we might answer the question whether the spleen developed normally 
and then infarcted, or never developed properly is by looking at the development of the 
spleen in humans. In family A, the mother of JL0627 is pregnant again. The monitoring 
of the spleen of the baby during pregnancy will be interesting. The interest will also 
depend on the genotype of the baby. The answer will come in a couple of months. 
7.2 RPSA haploinsufficiency in animal models  
One other way to test the hypothesis that the spleen never developed completely 
and perhaps the architecture of the vascular system of the spleen was impaired and led 
to this fibrosis and iron deposits, we started to look at animal models: the mouse model 
and the zebrafish model taking advantage of the conservation of RPSA in different 
species. The amino acid sequence of Rpsa in mouse is 99.3% identical to its human 
homolog and the amino acid sequence of Rpsa in zebrafish is 82% identical to its 
human homolog.  
Our collaborator Steven R. Ellis from the University of Louisville created a 
Rpsa+/- mouse model by inserting a neo-cassette replacing the first four exons of Rpsa 
(Material and Methods). The mice are currently being phenotyped at the Laboratory of 
Comparative Pathology at the Memorial Sloan-Kettering Cancer Center (MSKCC). 
Sixteen mice were sent for phenotyping at five weeks of age: 4 control WT mice, 8 mice 
Rpsa+/-, 2 mice Pbx1+/- and 2 mice Rpsa+/-,Pbx1+/-. The complete blood count results 
did not show any phenotype in the Rpsa+/- mice. The histology results on the spleens of 
these mice are not available yet. The results on the architecture and the vasculature of 
the spleen will be very important. In the meantime we dissected one Rpsa+/- female 
mouse at the age of five weeks, in the laboratory of Licia Selleri. The Rpsa+/- mouse 
presented a normal spleen in terms of size and weight (Figure 20). This is only one 
mouse and the results of the phenotyping at MSKCC will help to draw more 
conclusions. The complete knockout mouse dies at E3, well before the development of 
the spleen and thus does not allow any interpretable observation.  
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In addition to the mouse model, we took advantage of the zebrafish model 
organism. The zebrafish is an ideal system to study developmental defects as all the 
organs, the spleen in particular, form within 5 days and the fish remains transparent for 
that period of time112. In the laboratory of Nikolaus Trede at the Univeristy of Utah, we 
knocked down Rpsa using morpholinos (Figure 21). The first results were hard to 
interpret and the optimal levels of knocking down need to be optimized before we can 
assess the impact of Rpsa decrease on the zebrafish spleen using a Tlx1 probe at 5 
days of age113. Our work to elucidate the pathogenesis of ICA by looking at the 
macroscopic level is thus ongoing.  
7.3 Impact of RPSA haploinsufficiency at the molecular level 
A complementary approach to understand the role of RPSA in the mechanism of 
ICA is to look at the molecular level. Its best characterized function is its ribosomal 
function which can be divided into two. Firstly, RPSA is important in pre-rRNA 
processing114. Secondly, it is also an integral part of the small subunit of the 
ribosome115. The best described function of RPSA is its role in the processing of 18S 
rRNA (Figure 22A). In vitro studies have shown that RPSA is important in the pre-rRNA 
processing, particularly in the late stages for the processing of the 21S to the 18S 
rRNA114. We thus tested the pre-rRNA processing in the patients’ cells. We only had 
frozen peripheral blood mononuclear cells (PBMCs) available. In order to have enough 
cells to extract total RNA we activated these PBMCs with PHA for 3 days. In these 
conditions the T cells proliferate. The analysis by Northern blot of the RNA extracted 
after 72 hours did not reveal a strong phenotype. The intensity of the band 
corresponding to the 18SE form on the rRNA was as strong as the controls (Figure 
22B). Actually the 18SE band might be more intense when compared to the other 
bands (the 45S for example) and this might indicate a phenotype. The experiment 
needs to be repeated. Looking at other time points such as 24 or 96 hours might reveal 
a phenotype. Activating the PBMCs with PHA and then IL-2 should lead to an increased 
proliferation of T cells, and should thus be better conditions to observe a rRNA 
processing phenotype. Experiments looking more downstream of the pre-rRNA 
processing will be performed next. In particular it would be interesting to analyze the 
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cytoplasmic ribosomes on a sucrose gradient and look at the quantity of the 40S 
ribosomal subunit for example. One more experiment would be to look at the nucleolar 
morphology and chromatin condensation by FISH in the patients’ cells114.  
Finally we tried to understand how mutations in such a ubiquitous gene led to a 
spleen specific phenotype. We hypothesized that it was due to the level of expression of 
the protein in the spleen. Even though RPSA is ubiquitously expressed, it might be 
expressed at particularly low or high levels in the fetal spleen. For example if it were the 
ribosomal protein with the lowest expression in the fetal spleen, a supplementary 
decrease due to haploinsufficiency might lead to a defect in the spleen, whereas it 
would be not impair any function in cell types where RPSA is more expressed. We thus 
purchased mRNA extracted from human fetal spleen, human fetal heart, human fetal 
brain and human adult spleen and compared by Q-PCR the levels of RPSA. The first 
results did not show a major difference (Figure 23). However these results varied 
greatly depending on the gene used as a control (GAPDH or VCL for example). In order 
to decrease the impact of these control genes, we need to test more genes and 
probably more organs. Taken together our results need to be repeated and many 
experiments need to be performed to understand the impact of the mutations on the 
function of RPSA. Ultimately these results might help to understand the link with the 
spleen. 
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Figure 19: Spleen of a patient with a mutation in RPSA. 
Spleen from patient JL0423 (family F). The spleen was 1cm large and contained a large 
fibrous nodule with many iron deposits and few lymphoid follicles (Perls staining)116.The 
spleen is representative of the four spleens described from the post mortem analyses of 
ICA patients with mutations in RPSA.  
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Figure 19: Spleen of a patient with a mutation in RPSA. 
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Figure 20: Rpsa+/- mouse. 
The spleen of a control WT mouse (top) and the spleen of a Rpsa+/- mouse (bottom). 
Both mice were 5 weeks old when the spleen was analyzed. The weight and size of 
both spleens are comparable. 
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Figure 20: Rpsa+/- mouse. 
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Figure 21: Knockdown of rpsa in zebrafish. 
(A) Scheme of the rpsa gene in zebrafish. Rpsa is 308 amino acids in the zebrafish and 
has 8 exons. Exon 7 is different from human RPSA .The size of the exons and introns 
respect the scale. Shorter (in height) restangles represent the untranslated regions. 
Bigger (in height) rectangles represent the coding region. The localization of the 
morpholinos used to knockdown rpsa in the zebrafish is represented in red. From left to 
right: Rpsa-5UTR-MO-1, Rpsa-intr2ex3-MO-2, Rpsa-ex3intr2-MO-3. (B) Example of in 
situ hybridization results at day 5 with a Tlx1 probe113. The spleen of the zebrafish is 
indicated by the arrow. 
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Figure 21: Knockdown of rpsa in zebrafish. 
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Figure 22: RPSA is involved in pre-rRNA processing. 
(A) Pre-rRNA processing pathway in human cells. The main pathway is described114. 
The 18S-E pre-rRNA is converted to 18S rRNA in the cytoplasm. (B) Northern blot. 
Total RNA from PBMCs of controls and patients were extracted 72 hours after activation 
by PHA, resolved on a 1% agarose gel, and transferred to a nylon membrane, which 
was hybridized with 5’-ITS1 32P-labeled probe. Ratios of the intensity of the band 
45S/18S is indicated underneath.  
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Figure 22: RPSA is involved in pre-rRNA processing. 
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Figure 23: Expression of RPSA in different tissues. 
Poly A+ RNA was purchased from Clontech and was used to generate cDNA. Human 
fetal spleen (cat #636154), human fetal heart (cat #636156), human fetal brain (cat 
#636106) and human adult spleen (cat #636121). (A) To control that the human fetal 
spleen library came from the spleen, and that the heart library was not a spleen library 
TLX1 (specifically expressed in fetal spleen) mRNA levels were determined by 
quantitative RT-PCR using the Taqman assay. Threshold cycles normalized with 
respect to those of GUS (ǻCT) are plotted as 2-ǻCT. Results are then normalized with 
human fetal heart score. (B) RPSA mRNA levels were determined by quantitative RT-
PCR by the TaqMan assay (cat #Hs03046712_g1, Applied Biosystems). Threshold 
cycles normalized with respect to those of GUS (ǻCT) are plotted as 2-ǻCT. (C) RPSA 
mRNA levels were determined by quantitative RT-PCR by the TaqMan assay (cat 
#Hs03046712_g1, Applied Biosystems). Threshold cycles normalized with respect to 
those of VCL (ǻCT) are plotted as 2-ǻCT. 
  
99

Figure 23: Expression of RPSA in different tissues. 
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Table 11: Clinical phenotype of patients carrying a mutation in RPSA. 
Family:Patient
1
Ageof
Diagnosis
Spleen
(US/PM)

HJB Severe
Infections
(ageof1st
infection)
Heart CBC Other
A:JL0023 20years no(US) yes no normal haemoglobin
4.4g/dlat
age20y
dilatedveinsinthe
jejunumand
rectosigmoid.
angiodysplasia
A:JL0627 early
childhood
no(US) yes no2 normal normal /
B:JL0076 adult no(US) yes no normal normal /
B:JL0077 post
mortem
(23mo)
1cmlong
(PM)
NA yes(diedat
23mo)
normal NA /
B:JL0075 atbirth no(US) yes no2 NA normal /
C:JL0421 ? no ? ? normal normal /
C:JL0074 early
childhood
1.86cmx
0.5cm(US)
yes no2 normal normal /
D:JL0084 adult no(US) yes no normal normal /
D:JL0424 19mo no(US) yes no normal normal bornat29weeks
E:JL0431 adult no(US) yes no normal normal /
E:JL0429 7mo no(US) yes no2 normal normal /
F:JL0423 post
mortem
(22mo)
1cmx0.5cm NA yes(diedat
22mo)
normal NA /
F:JL0078 4days no(US) yes no2 normal normal osteosarcomaatage
of12y(lefttibiaand
leftknee)
G:JL0425 childhood no(US) yes no normal normal /
G:JL0086 childhood no(US) yes no normal normal /
H:JL0236 20mo small(US) ? yes(10mo) normal normal /
O:JL0628 20mo no(US) yes yes(2mo) normal normal /
T:JL0432 2years no(US) yes yes(8mo) normal normal /
US: ultrasound. PM: post mortem analysis. HJB: Howell-Jolly bodies. CBC: complete 
blood count. NA: not assessed. y: year. mo: month.  
1: the JL number in Figure 4 is used to identify the patients. Only certain ICA patients 
with a RPSA mutation are included. 
2: under prophylaxis treatment since early childhood. 
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8.1 ICA compared to PIDs, developmental defects and ribosomopathies  
We showed that RPSA is the major genetic etiology of ICA. More than 50% of 
the ICA patients in our cohort are mutated in this gene, and most notably 100% of the 
familial cases. This result is comparable to the recent discovery that 56% (15/27) of the 
patients with pancreas agenesis (the lack of a pancreas, an organ physically close to 
the spleen) present GATA6 haploinsufficiency117. This is however a very high 
percentage compared to the other PIDs studied in the laboratory. For example, 
mutations in TBK1 explain less than 1% of HSE cases118. The highest percentages 
observed in the lab were: 21% for the MSMD patients mutated in IL-12Rȕ1119, and close 
to 50% for the CMC patients mutated in STAT1120. The higher percentage of ICA 
patients mutated in RPSA might be explained by a more homogeneous cohort 
compared to other PIDs. This homogeneity highlights the accuracy of diagnosis by the 
physicians we collaborated with. Besides the great work of the physicians it also reflects 
the fact that it is easier to diagnose a patient with invasive pneumococcal disease and 
miss the ICA phenotype rather than the contrary. Therefore one would expect more 
heterogeneity in the IPD cohort than the ICA cohort. The biggest risks for a phenocopy 
of ICA are syndromic asplenia, meaning asplenia associated with other developmental 
defects. In this study the case reports of the patients recruited showed in one case gut 
malformations and in another case a heart defect. We removed these two cases from 
the study. 
Although we did not expect such a percentage of ICA cases mutated in the same 
gene, the biggest surprise came from the nature and function of RPSA. When we 
started the project we first hypothesized that mutations in TLX1 would be disease-
causing for the majority of the patients as the Tlx1-/- mice present ICA57. This was not 
the case. We then thought it could be allelic mutations in genes involved in asplenia 
syndrome or syndromic asplenia. This is why we investigated the mutation in NKX2-546 
(chapter 5). The experiments performed in the mouse model showed that Nkx2-5 is an 
important transcription factor involved in the development of the spleen. NKX2-5 is 
probably also involved in the development of the spleen in humans. However its role 
might be redundant with another gene or transcription factor. At least it is unlikely that 
103

the P236H heterozygous mutation in NKX2-5 identified in family B is responsible for the 
ICA phenotype due to the identification of a mutation in RPSA in this family. Finally, 
when we were analyzing the exome results for all patients we first hypothesized that a 
transcription factor would be identified. TLX1 (ICA in the mouse) is a transcription factor. 
GATA6 (pancreas agenesis) is a transcription factor. NKX2-5 (congenital heart defects) 
is a transcription factor. From what we know RPSA is not a transcription factor and 
unlike most transcription factors, it is expressed ubiquitously. From the perspective of 
spleen development this result is very surprising.   
RPSA is a ribosomal protein121. ICA could thus be classified as a new 
ribosomopathy. From the ribosome perspective, this result also stands out. So far, 
human disorders of ribosome dysfunction include Diamond-Blackfan anemia (DBA), 
Schwachman-Diamond syndrome (SDS), X-linked dyskeratosis congenita (DKC), 
cartilage hair hypoplasia (CHH), Treacher Collins syndrome (TCS) and the 5q-
syndrome122. Most of these disorders involve bone marrow failure, anemia and/or 
craniofacial or other skeletal defects. Haploinsuffciency in ten different ribosomal 
proteins including RPS19, RPS17, RPS24 and RPL5 explain about 60% of DBA 
cases122-125.  DBA is a congenital bone marrow failure syndrome characterized by 
hypoproliferative anemia and is associated with physical abnormalities. It was thus 
striking that our patients had no hematologic phenotype, in particular no anemia. 
Moreover some DBA patients also carry a broad range of developmental defects. For 
example the majority of patients with mutations in RPL5 have cleft palates or lip126, but 
none of the patients reported with haploinsufficiency in a ribosomal protein was 
diagnosed with ICA or with a spleen abnormality. By comparison, ICA is the 
ribosomopathy with the narrowest clinical phenotype in humans. Another major 
difference concerning the developmental defects in other ribosomopathies and ICA is 
the clinical penetrance. The penetrance is 100% in ICA whereas the penetrance for the 
physical abnormalities is very low in DBA patients. For example the R94X mutation in 
RPS19, identified in two sisters and their mother, led to thumb malformations and 
duplicated ureter in one sister, to congenital glaucoma in the other sister and had no 
effect in the mother123.  
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 8.2 Hypotheses regarding the pathogenesis 
Understanding the mechanism of pathogenesis and the link between RPSA and 
the spleen became the next challenge. The most relevant cells for these studies would 
be the spleen cells from human fetuses, not easily available for research purposes. 
Looking at the developing spleen in other organisms such as the mouse might be the 
most relevant experiment. We made the experiment. On one hand, haploinsufficiency of 
RPSA led to ICA in humans, a result that fits with the severity of the phenotype and the 
rare (n=1) non-synonymous polymorphisms in RPSA.  On the other hand, 
haploinsufficiency of Rpsa did not lead to any striking abnormality in the spleen in the 
mouse, although more phenotyping needs to be completed. Interestingly, 
haploinsufficiency of different ribosomoal proteins (RP), such as RPS19, in the mouse 
does not lead to DBA127. Similarly, Gata6 haploinsufficiency did not lead to pancreas 
agenesis in the mouse117. These observations suggest it might be required to knock 
down the genes by more than 50% to see a phenotype in the mouse. Therefore one 
alternative approach is to use transgenic models or conditional alleles allowing a 
complete deletion of Rpsa or a further reduction of Rpsa levels as compared to 
haploinsufficiency in an organ specific manner127. This would however be further away 
from imitating the human pathogenesis. Moreover the extreme phenotype (death at E3) 
of the Rpsa-/- mouse suggests that knocking out Rpsa completely in any organ would 
lead to the agenesis of this organ. We would thus need to conditionally knockout Rpsa 
in the spleen and at least one other organ as a control, making this experiment very 
costly. Moreover, an irreproducible phenotype in the mouse might still provide insight 
into the mechanism of pathogenesis. We can speculate that the difference between the 
two species is due to the promoter region as the protein sequences are almost identical. 
The human RPSA promoter might be weaker in the spleen.  
While in vivo studies are in process, we zoomed in and looked at the cellular 
level. The amino acids mutated in the patients carrying missense mutations are 
conserved in bacteria, yeast, plants and mammals. The high conservation of these 
amino acids even in prokaryotes suggests that they are involved/required for the 
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ribosomal function of the protein. This is why it will be important that the next 
experiments test extensively the ribosomal function of RPSA in the patients’ cells. Pre-
rRNA processing defects in human cells are associated to a red blood cell or 
erythropoiesis phenotype125. If we see a phenotype in vitro, we could speculate that the 
red blood cells have a direct involvement in ICA as the spleen is a blood filter, and the 
graveyard of red blood cells. The pathologists analyzing the necropsy of the four ICA 
patients in our cohort described the spleens as ‘infarcted’, similar to what happens in 
sickle cell anemia patients. Finally the fact that patients with HO-1 deficiency (3 cases) 
present anemia, hemolysis and asplenia84-86 might be one more link between anemia 
and asplenia. However asplenic patients did not present with anemia or a red blood cell 
phenotype making this hypothesis farfetched unless this phenotype is very transient, 
ahead of any infection and thus not detected by physicians.  
On the other hand ribosomal proteins are known to have extraribosomal 
functions128. RPSA was first discovered as a laminin receptor at the cell surface129. It 
was shown to be a receptor for prions or viruses130-132.  It was also associated with 
several diseases in humans, cancer particularly133-135. However none were very strong 
associations135. The most interesting phenotype observed might be that a functional 
retroposon of Rpsa caused right ventricular dysplasia in mice136. The authors showed 
that the retroposon was expressed in both ventriculars, but it led to a one-sided 
phenotype. Moreover the retroposon led to degradation of the myocardium even when 
injected in adult mice suggesting ICA might not come from a developmental defect but a 
later defect (the pathologist school). Finally they showed that the Rpsa retroposon could 
bind to HP1 and could lead to the change of expression of some specific genes136.  This 
study invites us to consider the role of tissue specific isoforms and/or pseudogenes in 
the disease. There are more than 2,000 pseudogenes for all human RPs. Their role is 
unknown. It also suggests that ribosomal proteins might influence the expression of a 
specific subset of genes. Microarray on the patients’ cells vs. their healthy siblings might 
bring novel insights in the role of RPSA. Moreover the lab of Maria Barna showed that 
Rpl38 haploinsufficiency specifically impaired the translation of Homeobox mRNAs, 
leading to axial skeleton defects137. Ribosome profiling experiments such as the ones 
performed in the lab of Davide Ruggero138 might answer this question, providing the 
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cells available are relevant. We believe using primary fribroblasts from some patients 
might be relevant, especially for the patient in family F who also developed 
osteosarcoma during childhood, knowing that osteoblasts and fibroblasts are very 
similar.   
One alternative way to identify which molecular pathway is involved in the 
pathogenesis of ICA is to identify a second etiology of ICA. By exome-sequencing we 
did not identify one gene significantly more mutated in the remaining exomes when 
compared to controls. As ALL ‘unexplained’ cases are sporadic cases, we made three 
different hypotheses. The first one is that there is second AD etiology, which equals that 
some of the ‘unexplained’ cases might be due to de novo mutations. Therefore we 
sequenced the exome of 7 trios, meaning we sequenced the exomes of 7 couples of 
parents of sporadic ICA cases (on top of the 7 patients’ exomes). Mutations present in 
the patient but not in the parents will be analyzed. The exomes are still being 
sequenced at the New York Genome Center for the time being. The second hypothesis 
is that some of these cases are due to AR mutations. Indeed if the second etiology was 
also AD, then some of the familial cases showing an AD mode of inheritance should 
have been mutated in the second hypothetical gene. It is not the case. Therefore it 
seems logical to look for recessive mutations. The analysis of the exomes with this AR 
perspective has not been successful so far. The third hypothesis is that some sporadic 
ICA cases are not due to a genetic lesion.  
The recruitment of additional patients would also increase our statistical 
approach to the analysis of exomes and might lead to a second genetic etiology. We 
need to maintain our efforts into the recruitment of additional patients. 
8.3 The consequences at the clinical level of this discovery 
This work was mainly done at the Rockefeller University, where the goal is to do 
Science for the benefit of humanity. The discovery of the genetic etiology of ICA has 
important clinical consequences. ICA is a life-threatening disease unless diagnosed at 
birth. Patients diagnosed early will be treated with preventive prophylaxis, protecting the 
patient from bacterial infections. However abdominal US to look at the presence of the 
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spleen are not routine procedures and thus physicians only diagnose ICA after a severe 
bacterial infection. If we could diagnose ICA using the whole genome sequence of the 
new-born, we would save the lives of all ICA patients. As every new-born will have its 
genome sequenced in the near future, this should save the lives of many ICA patients. I 
hope RPSA will be incorporated into the genetic screens performed in new-borns and 
that red flags will be raised when a mutation is detected in RPSA. Otherwise it might be 
worth to start a company selling a RPSA genotyping. At least this work set the basis for 
improved diagnosis and treatment of ICA in the future. One side effect of this discovery 
will be the increase of the number of disease-causing RPSA variants in the population!!  
What is true for ICA is true for all PIDs. If one knows that one is susceptible to 
one specific pathogen, one can take preventive treatment. This is not the case for most 
of the other genetic diseases where we still cannot change the outcome despite 
knowing the genetic etiology. This is also why the genetic theory of infectious diseases 
is so important clinically. The upper estimates suggest that six million people may be 
living with a PID worldwide139, but the single-gene theory of pediatric infectious diseases 
remains not too popular and often appears provocative. This is due to two reasons. 
First, the germ theory of diseases holds such sway that there is still some reluctance to 
think of infectious diseases in terms of human genetics. Second, the popularity of the 
“common disease-common variant” hypothesis and the fact that infectious diseases are 
the most common pediatric illnesses have resulted in resistance to thinking about 
pediatric infections as monogenic diseases. Rare pediatric illnesses are thought to be 
Mendelian, whereas common illnesses are thought to be infectious. However, many 
individual infectious diseases in children are less common than some well-known 
genetic diseases. Severe infectious diseases are globally common because there are 
many of them and some are common. The discovery of the genetic etiology of ICA 
argues in favor of the hypothesis that severe pneumococcal infections are the result of a 
single-gene lesion.   
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Recruitment of study participants 
Our research protocol was approved by the Institutional Review Board of Rockefeller 
University. Written informed consent for participation in the study was obtained from all 
patients and family members studied. 
DNA extraction 
Genomic DNA was isolated from the peripheral blood mononuclear cells (PBMCs) or 
the EBV-B cells of the patients and the family members using standard procedures.  
Whole-exome sequencing 
Genomic DNA (3ȝg) extracted from EBV-B cells from the patient was sheared with a 
Covaris S2 Ultrasonicator (Covaris). An adapter-ligated library was prepared with the 
Paired-End Sample Prep kit V1 (Illumina). Exome capture was performed with the 
SureSelect Human All Exon kit (Agilent echnologies). Single-end sequencing or paired-
end sequencing was performed on an Illumina Genome Analyzer IIx (Illumina), 
generating 72-base reads. Table 8 provides more details on the kit used as well as the 
coverage for each exome.   
Sequence alignment, variant calling and annotation 
We used BWA aligner140 to align the sequences with the human genome reference 
sequence (hg19 build). Downstream processing was carried out with the Genome 
analysis toolkit (GATK)88, SAMtools89 and Picard Tools (http://picard.sourceforge.net). 
Substitution calls were made with a GATK UnifiedGenotyper, whereas indel calls were 
made with a GATK IndelGenotyperV2. All calls with a read coverage 2x and a Phred-
scaled SNP quality of 20 were filtered out. All the variants were annotated with the 
GATK Genomic Annotator. For filtering purposes we used 1000 genomes (May 2011 
release based on 1094 individuals), dbSNP134 and an in-house database of about 600 
individuals.    
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Analysis of whole-exome sequencing  
P-values for each gene were calculated based on the script of Ionita-Laza109. The data 
from 623 individuals was used. 592 were controls, 30 were cases and one was 
removed. A total of 1,859,802 variants were analyzed. All the genes with more than 
2,000 variants were removed (n=20). The weighted sum with all rare variants (WS-R) 
was used to calculate the p-values for 21,185 genes.  
Sanger Sequencing of the coding region of RPSA 
The coding exons and intron/exon boundaries of RPSA were amplified by PCR and 
then sequenced using the Big Dye v3.1 kit on a 3730DNA Analyzer (Applied 
Biosystems). 
Primers used for sequencing of RPSA. 
Exon Forward/Reverse Sequence (5’ to 3’) 
1 Forward CCATACCATCTGTTCAATCTTG
1 Reverse CCGAAGGGATAGCAACACAG
2 Forward TGTGCCCTACTTAACTCAATGG
2 Reverse CAGAACTAACCACGAGAATAGC
3 Forward GCCTCTATGACTGGAGTTTGG
3 Reverse TGTCTCACAATGTCTGTAAGCT
4 Forward GGAGTAGTAGTGATTAAGTTGGC
4 Reverse CCTACACTTGCGAGTTCATCG
5 Forward GATGTAAGAGCCAGGAAGGTGC
5 Reverse TCCTAGAAGCACAGTCCAAGTC
6 Forward CTTGTGGTTACATAAGCAAATTGG
6 Reverse GCAGTCTATCAGATGCTGTAGC
7 Forward GCTACAGCATCTGATAGACTGC
7 Reverse GAAGTACAACTCATGTCGAGAC
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Multiplex Ligation-dependent Probe Amplification (MLPA) 
For the MLPA experiment we used the EK1-FAM reagent kit from MRC-Holland. We 
followed their protocol. 6 probes in the RPSA locus were designed as well as 4 control 
probes: 1 in BCAP31 on chr. X, 1 in SRY on chr. Y, 1 in SS18 on chr. 18, and 1 in IFNȖ 
on chr.12. Fragment analysis was done on Applied Biosytem 3730 Analyzer. 
Gene 
(exon) 
Left / 
Right 
Sequence 
BCAP31 L GGGTTCCCTAAGGGTTGGAACAGGAGCCTGAAGGCTGACCT
BCAP31 R GCAGAAGCTAAAGGACGAGCTGGACTTCTAGATTGGATCTTGCTGGCAC
SS18 L GGGTTCCCTAAGGGTTGGACAGCAGCCACCTATGGGAATGATG
SS18 R GGTCAAGTTAACCAAGGCAATCATATGATGTCTAGATTGGATCTTGCTGGCAC
SRY L GGGTTCCCTAAGGGTTGGACAGCGAAGTGCAACTGGACAACAGGTTGTA
SRY R CAGGGATGACTGTACGAAAGCCACACACTCTAGATTGGATCTTGCTGGCAC
RPSA(1) L GGGTTCCCTAAGGGTTGGAAAAAGCCCAGTCCCGGCAGCGTTCTT
RPSA(1) R CTCCGGCTCCGCCCTTCTTCCGCTCGACTTTCTTTTCTAGATTGGATCTTGCTGGCAC
RPSA(2) L GGGTTCCCTAAGGGTTGGAGACTGACTGACTGACTGACATGAAAAGAAATAGGTTGCTCTCTTATTTCA
RPSA(2) R GATTCCCGTCGTAACTTAAAGGGAAATCTAGATTGGATCTTGCTGGCAC
RPSA(3) L GGGTTCCCTAAGGGTTGGACAAGTGTTACAAATCCTTCTGCCCTCACTTAG
RPSA(3) R GCATCTATATCATAAATCTCAAGAGGACCTGGGTCTAGATTGGATCTTGCTGGCAC
RPSA(4) L GGGTTCCCTAAGGGTTGGAGAATATCGAGTACCACTAACTTTTAAATTCTTCAAAG
RPSA(4) R AGGGCTGTGCTGAAGTTTGCTGCTGCCACTGGAGCTCTAGATTGGATCTTGCTGGCAC
RPSA(5) L GGGTTCCCTAAGGGTTGGAGGTCATGCCTGATCTGTACTTCTACAGAGATCCTGAAGAG
RPSA(5) R GTAAGCTTCTCCAAAGGCTTGTGGTTACATAAGCAAATTGGTCTAGATTGGATCTTGCTGGCAC
RPSA(7) L GGGTTCCCTAAGGGTTGGATACATTGAGGACAGAGCTGATGGCTTTTTTTGGTATTCTCTTAACAG
RPSA(7) R AAGACTGGAGCGCTCAGCCTGCCACGGAAGACTGGTCTGCAGCTCCCTCTAGATTGGATCTTGCTGGCAC
IFNɶ L GGGTTCCCTAAGGGTTGGATTGACTTCTCAGACTCTAAGGTCAAGATTAGCATTAAAAAGGT
IFNɶ R AATAGGAAATGTTTACAAATTAAAGTCAAAAAGGTCCTTAAATCTAGATTGGATCTTGCTGGCAC
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Multiple species alignment 
Conservation of RPSA [GenBank ID: NP_002286.2] was assessed by aligning all 
orthologs of RPSA obtained from release 65 of Homologene 
(http://www.ncbi.nlm.nih.gov/homologene, Homologene ID= 68249).  
Quantitative RT-PCR 
Poly A+ RNA was purchased from Clontech and was used to generate cDNA with the 
SuperScript III First-Strand Synthesis System (Invitrogen). Human fetal spleen (cat 
#636154), human fetal heart (cat #636156), human fetal brain (cat #636106) and 
human adult spleen (cat #636121) were purchased. The expression of RPSA was 
assessed in the TaqMan gene expression assay (cat. Hs03046712_g1, Applied 
Biosystems), with normalization of the results as a function of GUS (ɴ-glucuronidase) or 
VCL gene expression. 
Western Blot 
Laminin-R (H-141) (sc-20979) was used for all blots to detect endogenous RPSA.  
Rpsa +/- mouse 
The strategy used to create a RPSA knockout mouse was designed and implemented 
by InGenious Targeting Laboratories.  A 14kb DNA fragment flanked by Not1 restriction 
sites containing exons 1-7 of the mouse RPSA gene was isolated from a 129/SvEv 
lambda genomic library.  A Neo cassette was used to replace sequences including 
exons 1-4 of RPSA.  The sequence replaced begins with 5ƍ-
GCAATACCACGGCCCAGCAGCAGTTAG-3ƍ and ends with 5ƍ-
GAGTGGCTCCTGTGGCAGCAGCAA-3ƍ.  The targeting vector was linearized by Not1 
and electroporated into iTL1 (129/SvEv) embryonic stem cells.  After G418 selection 
surviving colonies were screened by Southern blot analysis using a 570 bp PCR 
fragment produced using the primer pair: PB1 (4.3kb upstream of exon 1) 5ƍ-
CTTTCTCCCTTGTGTCCATCACAG-3ƍ and PB2 (3.7kb upstream of exon1) 5ƍ-
TTTCCTTGCTGAGGCATCTCACTG-3ƍ.  For Southern blotting mouse genomic DNA 
was cleaved with HindIII and hybridized with the probe described above.  The expected 
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size of the wild-type fragment hybridizing with this probe was 7.8kb and the knockout 
fragment 2.8kb.   
ES cell lines containing the RPSA targeted construct were microinjected into C57BL/6J 
blastocysts and the resulting chimeric mice were set up for germline transmission of the 
disrupted RPSA allele.  Mice were screened using the Southern blot strategy outlined 
above or using two PCR primer pairs.  One primer pair was to the sequences within the 
Neo cassette: 5ƍ-CTCTTCAGCAATATCACGGGTAGCCA-3ƍ and 5ƍ-
GCTCCTGCCGAGAAAGTATCCATCAT-3ƍ which gives a 371bp fragment in the 
knockouts and 5ƍ-TTACACAATGTCCGGAGCCCTTGA-3ƍ and 5ƍ-
ACAAGCCAGAGTAGCACTCCAACA-3ƍ which gives a 240bp fragment from wild-type 
mice.   
Mice were housed in Licia’s Selleri mouse room at Weill Cornell Medical school and 
were phenotyped by the laboratory of Comparative Pathology at MSKCC. Phenotyping 
included complete blood count with blood smear, measure and weigh of the spleen, 
analysis of the spleen shape and histology of the spleen.  
Rpsa +/- zebrafish 
Morpholinos were designed to target either the 5’-UTR of Rpsa, before the ATG or the 
splicing of exon 3. The number of base pairs in exon 3 is not a multiple of 3 and thus 
impairing the splicing of this exon should lead to a premature STOP. The sequences 
are:  
Rpsa-5UTR-MO-1: CCACTTTCCCTGCGTAACGAGTTTA 
Rpsa-intr2ex3-MO-2: ACGCCTGCAGAAATACAATTAGAGC 
Rpsa-ex3intr3-MO-3: ACGCCTGCAGAAATACAATTAGAGC 
Morpholinos knocking down p53 were also used to prevent excessive toxicity.  
Pre-rRNA processing 
These experiments were performed by Steven R Ellis using the protocol described 
previously141.   
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CONCLUDING REMARKS 
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The field of human genetics of infectious diseases is a small subgroup of the 
fast-growing field of human genetics. In four years, I became fascinated by human 
genetics and the impact that small changes in the DNA or RNA can have on the human 
body. I was also very fortunate to be part of this field during a major revolution: the 
advent of whole-exome sequencing. This technology changed the outcome of this 
project, and is changing the entire field. The pace of discovery of the genetic etiology of 
Mendelian diseases is increasing exponentially, and there is no doubt that exome 
sequencing will come to the clinic soon. A likely, most interesting change that I predict is 
on the horizon is the merge of the fields of the human population genetics and 
Mendelian genetics. In my opinion one of the main dividing factors between the two 
schools was purely technical. It was too expensive for population geneticists to 
sequence genes entirely in a large cohort. That is now possible. The Mendelian 
geneticists will have to adapt. Firstly, there is a need to find more efficient methods to 
recruit patients for Mendelian disorders. Secondly, there is a need to use more statistics 
to be on par with the population geneticists. The example of NKX2-5 is the perfect 
example to illustrate this. Despite all the functional work that ‘proves’ the mutation to be 
disease-causing in family B, the genetic work on a larger number of patients showed 
that in fact the mutation was not disease-causing. 
Clinically, the low cost of sequencing will also improve diagnosis and prognosis. 
Rare diseases are usually not well diagnosed. For example the lab started to recruit 
patients with rhinoscleroma, an infectious disease affecting the upper respiratory tract. 
After sequencing the exome of two patients from the same family, we found that these 
patients suffered from SLC29A3 deficiency59, a disease that has nothing in common 
with rhinoscleroma. Actually we might not need physicians in the future for the 
diagnosis, at least for pediatric infections or pediatric diseases in general. Everyone (or 
a cloud-based program) will be able to proffer a diagnosis based on the patient’s 
genome. The availability of more genomes will also enable research on many more 
traits, in particular non disease-causing traits. If a platform where individuals can share 
their genome, as well as their phenotype is equipped with open-access genome 
analysis programs, it might lead to many and very interesting discoveries.  
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